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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
The first step of glycolysis is catalyzed by hexokinase (ATP: D-hexose-6-
phosphotransferase, EC 2.7.1.1).  Hexokinases catalyze the transfer of γ-phosphoryl 
group from adenosine triphosphate-magnesium complex ([ATP-Mg]2-) to glucose at 
the 6-hydroxyl position producing glucose-6-phosphate (Glc-6-P) and adenosine 
diphosphate (ADP) (1-3).  Four hexokinase isozymes are identified in mammalian 
tissue: I, II, III and IV (1,4) (Table 1.1).  Hexokinases I-III have molecular weights of 
100 kDa and approximately 70% sequence identity (5).  Hexokinase IV is a 50 kDa 
protein with sequences similar to the C- and N-halves of hexokinases I-III (5). 
Hexokinase I (HKI) or brain hexokinase is recognized as the “pacemaker of 
glycolysis” in brain tissue and the red blood cell (6).  HKI is highly expressed in 
kidneys, liver, intestines and lungs (3,7).  Heart, muscles, lungs, intestines and 
adipose tissue are the major tissues that produce HKII (3,7).  HKIII is relatively 
abundant in lungs, liver and spleen (3,7).  Presumably, hexokinases I-III have evolved 
by the duplication and fusion of a primodial gene similar to that of yeast hexokinase 
(8,9).  The N-and C-terminal halves of HKI and HKII exhibit significant sequence 
similarities (10).  Both halves of HKII support catalysis and are each sensitive to 
inhibition by Glc-6-P (11), whereas only the C-terminal half of HKI supports activity 
(12).  Solution studies of native HKI reveal only one high-affinity binding site for 
Glc-6-P (13-15). X-ray crystal structure of HKI, however, shows Glc-6-P binding to  
  
Table 1.1. Mammalian hexokinase isoenzymes. 
Properties HKI HKII HKIII HKIV 
MW (kDa) ~100 ~100 ~100 ~50 
KmGlc (mM) 0.03 0.3 0.003 6 
KmATP (mM) 0.5 0.7 1.0 0.6 
C-half activity + + +  
N-half activity - + -  
KiAnGlc-6-P (mM) 0.02 0.02 0.1 - 
Glc-6-P inhibition (C-half) + + ?  
Glc-6-P inhibition (N-half) + + ?  
Pi relief of Glc-6-P inhibition + - - - 
Tissue 
Brain, kidney, 
red blood cells 
Muscles, 
lung, adipose 
Lung, liver, 
spleen 
Liver, 
pancrease 
Mitochondrial binding + + - - 
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both N- and C- terminal halves (16-18). Previous observations are in agreement with 
only one of the two Glc-6-P sites is available for functional ligand binding in solution. 
Two models are proposed to explain HKI inhibition by Glc-6-P and the relief of 
inhibition by phosphate (Pi). In the first model, Glc-6-P binds to N-terminal half 
causing inhibition of the catalytically active C-terminal half by an allosteric 
mechanism (12). Pi binding to N-terminal half is mutually exclusive with Glc-6-P 
(18-20). In the second model, Glc-6-P directly binds the catalytically active C-
terminal half (19-21). Pi binds to N-terminal half and reliefs Glc-6-P inhibition by an 
allosteric mechanism (18-20).  It is proposed that Glc-6-P sensitive binding site has 
evolved from an ancestral catalytic site (8). At high concentrations, Pi can bind to the 
active site and inhibit HKI (17).  Pi does not relieve Glc-6-P inhibition of the HKII 
(18).  ADP is a mixed inhibitor for both HKI and HKII (7).  ADP inhibits HKI by 
binding to both the active site and a second allosteric site (2,22-26).  Free adenosine 
triphosphate [ATP]4- is a competitive inhibitor in relation to [ATP-Mg]2-, the true 
substrate for HKI. 
The X-ray crystal structure of recombinant human HKI reveals a dimer of 
identical HKI molecules (Fig.1.1).  The subunit consists of C- and N- terminal 
domains separated by a transition helix (16).  In the crystalline complex of HKI with 
glucose (Glc) and Glc-6-P, both ligands bind in proximity to each other at the C- and 
N-terminal halves (16,18) (Fig. 1.2).  Mutational analysis showed that C-and N-
terminal Glc-6-P sites, can independently inhibit HKI (27).  Crystallizing HKI with 
Glc and Pi revealed a binding site for Pi at N-terminal half (16) (Fig. 1.3).  Mutations 
in the Glc-6-P pocket at N-half did not prevent Glc-6-P inhibition; however, Pi-relief  
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of Glc-6-P inhibition was compromised (27).  Mutating residues in Glc-6-P binding 
pocket at the C-terminal half did not affect Glc-6-P inhibition or Pi-relief of Glc-6-P 
inhibition (27).  Similar to yeast hexokinase, the C-terminal of HKI has two 
conformational states: open and closed (16,18) (Fig. 1.2, Fig. 1.3).  The 6-phosphoryl 
moiety of the Glc-6-P overlaps the binding site of the α-phosphoryl group of ATP in 
the C-terminal half (18,21).  On the other hand, the same group overlaps the binding 
site of Pi in the N-terminal half (16,18).  Homology modeling with yeast hexokinase 
and other adenine nucleotide binding proteins was used to develop a model for ATP 
binding site in HKI (28).  Many residues in ATP binding pocket were tested by site 
directed mutation and proved to be essential for transition state product ADP-
hexokinase stabilization (29-31).  Corresponding mutations in the vestigial adenine 
nucleotide binding site at N-half caused significant loss of Pi induced relief of Glc-6-
P inhibition (31).  Subsequently crystals of an engineered monomer of HKI revealed 
ADP binding to the active site of the C-terminal half and an additional nucleotide 
binding sites at the N-half that is remote from the vestigial active site (21) (Fig. 1.4). 
HKI binds the outer mitochondrial membrane (OMM) in brain tissue (32).  
Mitochondria-associated HKI has preferential access to newly formed mitochondrial 
ATP (32).  HKI binding to the mitochondrion prevents the opening of the 
permeability transition pore (PTP) (33).  The PTP putatively consists of the adenylate 
translocator (ANT) of the inner mitochondrion membrane, and the voltage dependent 
anion channel (VDAC) of the outer mitochondrion membrane (34-39).  The PTP is 
regulated by cyclophilin D of the inner mitochondrion matrix and the binding of 
hexokinase I and II (40-42).  HKI likely interacts with VDAC to close PTP opening  
  Fig. 1.4. Nucleotide
(magenta). 
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(34-35).  Open PTP results in loss of membrane potential, organelle swelling, 
cytosolic acidification, and the release of cytochrome c (33,40).  Released 
cytochrome c activates the caspase family of proteases and initiates apoptosis (42-44).  
Another line of evidence suggests that pro-apoptotic proteins such as Bax trigger 
cytochrome c release without mitochondrial swelling (40,45,46).  Pro-apoptotic 
proteins (Bax, Bak, and Bim) assemble with VDAC in large channels used to release 
of cytochrome c (45-47).  Mitochondrion-associated hexokinase II antagonizes the 
formation of these channels (48-50).  Overexpression of VDAC-1 causes apoptotic 
cell death (51,52), however, over expression of N-terminally truncated VDAC-1 did 
not induce cells to release cytochorme c and the cells were resistant to apoptosis (53).  
N-terminus peptide and other VDAC-1 based peptides bind to immobilized HKI (54).  
These peptides prevented HKI protection of cells (53,54).  Chemical modification or 
mutation of residue Glu 72 prevented HKI binding to mitochondria and prevented it 
protection against apoptosis in different cancer cells (51,55). HKI binding to VDAC-1 
in reconstituted in lipid membrane decreased channel conductance (33).  HKI failed 
to bind to mutant mVDAC E72Q in reconstituted in lipid membrane (55). 
HKI association with mitochondria requires fifteen, largely hydrophobic 
amino acid residues at the N-terminus (56).  Exposing HKI to proteases results in loss 
of mitochondrial binding (57).  Using rapid purification procedures such as HPLC 
decreases the mitochondria non-binding portion of rat brain hexokinase (58,59). 
Hydrophobicity of mitochondria-binding rat brain hexokinase is higher than that non-
binding form (60).  Mitochondria binding and non-binding forms of HKI have similar 
molecular weight and kinetic properties (61).  The N-terminal peptide from rat brain 
10 
 
does not yield to chemical sequencing (62), being blocked most probably by an acetyl 
group (63).  The first 11 residues of HKI N-terminus are proposed to have a helical 
conformation (62).  A helical conformation facilitates the insertion of the N-terminal 
segment in the OMM in lipid bilayer (62-64).  Monoclonal antibodies against rat 
brain hexokinase inhibited both mitochondrial binding and Glc-6-P induced release 
(65,66).  Structural determinants for HKI-association must be contained in the 
hydrophobic tail, but single-residue determinants have not been identified.  A 
contribution of thesis work here is the discovery of single-residue determinants 
essential for the binding of HKI to mitochondria. 
Many small and physiological important ligands dissociate HKI from the 
OMM.  The most relevant releasing ligands are nucleotides and Glc-6-P (32).  Using 
a wild-type recombinant HKI with properties comparable to native brain hexokinase, 
including those of mitochondrial-binding and release, Skaff et al. (67) demonstrated 
that Glc-6-P-induced release of mitochondria-bound HKI follows a simple 
equilibrium model.  In this model, ligand-bound HKI partitions between solution and 
OMM. Mutating the Glc-6-P binding site at N-terminal half of HKI, increased the 
Glc-6-P concentration necessary for 50% release of mitochondria-bound HKI by 7-
fold.  Although nucleotide-induced release of HKI from mitochondria was observed 
as early as Glc-6-P release (32,68-70), the mechanism of nucleotide release remained 
unclear.  Adenine nucleotides can induce mitochondrial release by either binding to 
HKI itself or to VDAC.  Three possible sites exist on HKI: (a) the active site at the C-
terminal half (5), (b) the Pi binding site at the N-terminal half (21), and (c) the 
nucleotide pocket of unknown function near the N-terminal membrane targeting 
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element (21,71).  VDAC-1, on the other hand, has multiple nucleotide binding sites as 
shown by photoactive ATP analog, Bz-ATP (benzoyl-benzoyl-ATP), studies (72).  
Mutated nucleotide-binding VDAC-1 affects cellular growth levels negatively (73).  
We propose that nucleotide-induced release of HKI mitochondria follows a mutually 
exclusive binding model.  In this model HKI and nucleotides compete for a common 
binding site on VDAC1 at the OMM.  
The major contribution of this dissertation is to establish an ATP induced 
release model and to identify binding determinants in the HKI hydrophobic tail.  
Properties of binding of fluorescent nucleotide analogs to HKI were also investigated. 
Dissertation Organization 
 This dissertation is organized into five chapters. Chapter 1 covers the 
literature related to the research project.  Problems and objectives of the thesis 
research are provided as well.  Chapters 2, 3 and 4 are papers prepared for submission 
for publication in peer reviewed journals.  Chapter 2 is a determination of the 
mechanism of nucleotide release of HKI from OMM.  Chapter 3 shows that the N-
terminal hydrophobic tail has specific and essential amino-acid determinants that 
stabilize the binding of HKI to the mitochondrion.  Chapter 4 describes the specificity 
of nucleotide and TNP-nucleotide binding to HKI under different conditions of 
ligation. Conclusions and recommendations for future studies are in Chapter 5. 
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CHAPTER 2. MECHANISM OF ATP-DEPENDENT RELEASE OF 
WILD-TYPE AND MUTANT HUMAN BRAIN HEXOKINASES 
FROM MITOCHONDRIA1 
A paper to be submitted to the Journal of Biological Chemistry 
 
Nimer Mehyar2, Muneaki Watanabe, Lu Shen, Andrew D. Skaff, and Richard B. 
Honzatko2,3  
 
Abstract 
 Adenosine 5′-triphosphate (ATP) can release hexokinase I (HKI) from its 
binding site on the outer mitochondrial membrane, but the mechanism of ATP release 
of HKI from mitochondria is unclear.  ATP binds to the C-terminal half of HKI as a 
substrate and to the N-terminal half near the membrane binding element.  ATP may 
also bind to the voltage dependent anion channel (VDAC), the integral membrane 
component that putatively targets HKI to the mitochondrion.  The fluorescent 
nucleotide analogue 2′,3′-O-(2,4,6-trinitrophenyl) adenosine 5′-diphosphate (TNP-
ADP) binds with high affinity to the C-terminal half of HKI (Kd = 0.79 ± 0.09 µM) 
                                                 
1
 This research was supported in part by National Institute of Health Research Grant 
NS 10546. 
2
 Graduate student and professor, respectively, Department of Biochemistry, 
Biophysics and Molecular Biology, Iowa State University. Research conducted and 
manuscript written by Mehyar with assistance from Muneaki, Shen, Skaff and 
Honzatko. 
3
 To whom correspondence should be addressed. 
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and to VDAC (Kd = 1.3 ± 0.1 µM), but not to the N-terminal half of HKI (Kd > 50 
µM).  ATP competes with TNP-ADP for binding sites on HKI (KA = 190 ± 20 µM) 
and VDAC (KA = 550 ± 40 µM), but CTP does not displace TNP-ADP from either 
HKI or VDAC.  Other trinitophenyl nucleotides (TNP-ATP, TNP-AMP, and TNP-
CTP) bind with high affinity to HKI and VDAC.  ATP and trinitrophenyl nucleotides 
individually release wild-type HKI from mitochondria; however, CTP is ineffective as 
an agent of release.  ATP and ADP-TNP release the truncated N-domain of HKI from 
mitochondria, excluding nucleotide binding to either the N- or C-half of HKI in the 
release mechanism.  Results here are consistent with a release mechanism caused by 
the binding of ATP or TNP-ADP to VDAC. 
Introduction 
 Mammalian tissue contains four hexokinase isozymes: I, II, III and IV (1).  
Hexokinase I (HKI) or brain hexokinase has long been recognized as the “pacemaker 
of glycolysis” in brain tissue and the red blood cell (2).  Human brain comprises less 
than 2% of body weight and yet it utilizes at least one-quarter of the circulating blood 
glucose and approximately one-fifth of the oxygen consumed by the body (3).  
Nevertheless, HKI is at least 95% inhibited under normal physiological conditions in 
brain tissue (2).  A number of ligands inhibit HKI; however, glucose 6-phosphate 
(Glc-6-P) is probably the primary physiological inhibitor of the Type-I enzyme (4). 
On the other hand, inorganic orthophosphate (Pi) is capable of ameliorating Glc-6-P 
inhibition under normal physiological conditions (5), although at elevated levels it 
inhibits HKI by binding to the active site (6).  Hexokinase II (HKII) is functionally 
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similar to HKI; however, Pi does not relieve Glc-6-P inhibition of the Type-II isozyme 
(7). 
HKI and HKII have evolved by the duplication and fusion of a primodial 
hexokinase gene similar to that of yeast hexokinase (8).  Each half of HKI and HKII 
exhibits significant sequence similarities (9).  For HKII both halves support catalysis 
and are each sensitive to inhibition by Glc-6-P (10), whereas only the C-terminal half 
of HKI supports activity (11).  Nonetheless, both halves of HKI can bind Glc-6-P 
with high affinity, and moreover the binding of Glc-6-P to either half inhibits activity 
(12,13).  Pi binds with high affinity to the N-terminal half of HKI (14-15), and 
relieves Glc-6-P inhibition by an allosteric mechanism that couples both halves of the 
enzyme (15). 
HKI and HKII associate with the outer mitochondrial membrane in brain 
tissue (16).  This interaction requires fifteen, largely hydrophobic amino acid residues 
at its N-terminus (17).  HKI association with outer mitochondrial membrane allows 
preferential access to newly formed mitochondrial ATP (16).  HKI likely interacts 
with the voltage-dependent anion channel (VDAC) of the outer mitochondrial 
membrane (18-19).  HKI binding to the mitochondrion prevents the opening of the 
permeability transition pore (PTP) (20).  The PTP is a multicomponent system that 
includes the adenylate translocator (ANT) of the inner mitochondrion membrane, and 
the voltage dependent anion channel (VDAC) of the outer mitochondrion membrane 
(18-24), and is regulated by cyclophilin D of the inner mitochondrion matrix and the 
binding of hexokinase I and II (25-27).  Opening of the PTP results in loss of 
membrane potential, organelle swelling, cytosolic acidification, and the release of 
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cytochrome c (20,25).  Cytochrome c that escapes the mitochondrion after the PTP 
opening activates the caspase family of proteases, which ultimately results in 
apoptosis (27-29). 
Others maintain that the opening of the PTP initiates necrosis, but not 
apoptosis, and that a pro-apoptotic protein such as Bax, triggers the release of 
cytochrome c without mitochondrial swelling (25,30-31).  Nevertheless, 
mitochondrion-associated hexokinase II clearly antagonizes the action of pro-
apoptotic factors such as Bax (32) (33-34).  Pro-apoptotic proteins (Bax, Bak, and 
Bim) interact with VDAC in the assembly of large pores that presumably serve as 
conduits for the release of cytochrome c (30-31,35).  Indeed, over-expression of 
VDAC-1 causes apoptotic cell death (36-37).  Hexokinase I and II, through their own 
associations with VDAC, may antagonize the formation of apoptotic channels.  Some 
have gone so far as to label hexokinase as “guardian of the mitochondria” (38).  
Hexokinase colocalizes differentially with human VDAC1, 2 and 3 (39).  Hexokinase 
binding to mitochondria inhibits ATP flux through VDAC-1 (40).  Over expression of 
N-terminally truncated VDAC-1 did not induce cells to release cytochorme c and the 
cells were resistant to apoptosis (41).  The N-terminal peptide of VDAC-1 and other 
VDAC-1 based peptides bind to immobilized HKI.  These peptides prevented 
protection of cells by HKI (42).  Chemical modification of Glu 72 eliminated the 
binding of HKI to mitochondria (36).  Mutating Glu 72 and other residues abolished 
overexpressed HKI protection against apoptosis in different cancer cells (43).  Adding 
HKI to VDAC-1 reconstituted in lipid membrane reduced the channel conductance 
(20).  HKI addition to mutant (Glu 72 to glutamine) mouse VDAC reconstituted in 
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lipid membrane did not lessen channel conductance, indicating failure of HKI to bind 
to mutant VDAC-1 (43). 
A number of small and physiological important ligands are capable of 
dissociating HKI from the mitochondrial outer membrane.  These compounds include 
Glc-6-P and ATP (16).  Skaff et al. (44) demonstrated a wild-type recombinant HKI 
with properties comparable to native brain hexokinase, including those of 
mitochondrial-binding and release.  Their recombinant construct has an intact 
membrane targeting element and a formyl group attached to the amino terminus of the 
polypeptide chain.  The release properties of mutant constructs demonstrated the 
significance of Glc-6-P binding to the N-terminal half of HKI in promoting the 
release of the mitochondrion-associated enzyme.  The Glc-6-P release phenomenon 
adheres to a simple equilibrium model.  To date, little is known regarding the 
mechanism of ATP-induced release of HKI from mitochondria (16,45-47).  Three 
binding sites exist on HKI for adenine nucleotides: the active site at the C-terminal 
half (11), the Pi binding site at the N-terminal half at which the nucleotide may bind 
through its terminal phosphoryl group (48), and the nucleotide pocket of unknown 
function near the N-terminal membrane targeting element (48-49).  Photoactive ATP 
analog, Bz-ATP (benzoyl-benzoyl-ATP), can bind to more than one sites on VDAC-1 
with low and high affinities (50).  Mutating residues in predicted nucleotide-binding 
site in VDAC-1 reduced ATP cellular levels and caused retarded cell growth (51). 
The purpose of the present study was to investigate the mechanism of HKI 
release from mitochondria by adenosine nucleotides, and which, if any, of the adenine 
nucleotide binding sites of HKI or VDAC are responsible for that release.  The 
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fluorescent ADP analog, 2′,3′-O-(2,4,6-trinitrophenyl) adenosine 5′-diphosphate 
(TNP-ADP), binds with high affinity to single sites at the C-terminal domain of HKI 
and to VDAC.  Nevertheless, TNP-ADP releases the N-terminal domain of HKI (a 
domain to which it does not bind) from mitochondria.  The data here are consistent 
with a site on VDAC that binds HKI and ADP-TNP in a mutually exclusive manner. 
Experimental Procedures 
 Materials—ATP, ADP, chloramphenicol, deoxyribonuclease (DNase I), bovine 
serum albumin (BSA), leupeptin, protease cocktail inhibitor and 
phenylmethylsulfonyl fluoride came from Sigma.  Kanamycin sulfate and 2′,3′-O-
(2,4,6-trinitrophenyl)-derivatives of ATP, ADP, AMP, and CTP came from Invitrogen.  
DEAE HPLC was from Tosohaas.  Nickel-nitrilotriacetic acid-agarose (NiNTA) and 
Rosetta (DE3) competent cells were from Novagen.  Glucose-6-phosphate 
dehydrogenase was obtained from Roche Molecular Biochemicals.  Isopropyl-1-thio-
β-D-galactopyranoside (IPTG) came from Anatrace.  His-tag anitbodies, N-terminal 
HKI antibodies and C-terminal HKI antibodies were from Abcam.  Substrates for the 
3,3′,5,5′-tetramethylbenzidine enzyme-linked imunoabsorbant assay (TMB-ELISA) 
and western blotting chemiluminescence came from Pierce. Oligonucleotides came 
from the Iowa IDT. Lauryldimethylamine-N-oxide (LADO) was purchased from 
Affymetrix. 
 Construction of Wild-type Hexokinase and N-domain Plasmids—Human brain 
hexokinase (HKI) was cloned into pET-24b vector with a 10-residue histidine tag at 
its C-terminus (pET-24b-HKI-10xHis) as reported previously (44).  Hexokinase 
23 
 
mutants were created through PCR modification.  An NdeI cut site was created at 
Ala454 in pET-24b-HKI-10xHis using the forward primer, 
5’-GCAGCGGCAAGGGGGCTCATATGGTGACGGCGGTGGC-3’, and its reverse 
complement.  Mutant plasmid was digested with NdeI and then ligated to produce 
pET24b-N-HKI-10xHis.  This plasmid encodes residues 1-454 of HKI with a C-
terminal polyhistidyl tag (hereafter N-domain HKI). 
 Mitochondrion Purification— Pig livers were obtained from the Iowa State 
University Meats Laboratory shortly after slaughter.  Mitochondrial purification is 
described (52) with modification as discussed elsewhere (44).  Both outer 
mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM) 
integrities were measured as described previously (53-54).  Mitochondria were stored 
at –80º C in the presence of 5% dimethyl sulfoxide. 
 Expression and Purification of Wild-Type HKI and N-domain HKI— E.coli 
strain Rosetta (DE3) cells were transformed with wild-type or N-domain HKI 
plasmids.  Expression and purification HKI enzymes are discussed in detail by Skaff 
et al (44).  The determination of protein concentration employed the Bradford method 
with bovine serum albumin as a standard (55). 
 HKI Activity Assay—Hexokinase activity was measured using the glucose 6-
phosphate dehydrogenase (G6PDH)-coupled spectrophotometric assay.  All assay 
solutions had 3mM MgCl2, 3 mM DTT, 0.3 mM NADP, 10 µg/mL G6PDH and 50 
mM Tris-HCl, pH 8.0.  Concentrations of substrate (either glucose or ATP:Mg2+ at1:1 
ratio) varied from 1/5 to 5 times Km.  NADPH production was monitored at 340 nm.  
24 
 
G6PDH was in sufficient excess so that a doubling of HKI concentration resulted in a 
doubling of initial velocity.  Assays were initiated by addition of 0.5 µg HKI.  Initial 
rates were determined from slopes of linear progress curves (monitored for 3 minutes).  
Initial-rate data were analyzed using the GraFit computer program (56). The 
mechanism of TNP-ADP inhibition was determined by assays in the presence of 
saturating glucose (1.6 mM) and systematic variations in the concentration of 
ATP:Mg2+ at1:1 (0.3-4.5 mM) and TNP-ADP (0-40µM).  Mitochondrion-bound 
hexokinase was added to the assay cocktail with saturating glucose (1.6 mM) and 
saturating ATP:Mg2+, 1:1 (6 mM).  Initial velocity data were fit to models described 
in the Results section by nonlinear least squares using GraFit (56). 
 Mitochondrial Binding and Release— Purified HKI was dialyzed twice 
against mitochondrial-binding buffer (250 mM sucrose, 5 mM Glc, 50 mM NaCl, 5 
mM MgCl2 and 50 mM HEPES, pH 7.4), and then diluted to 2 mg/mL using the same 
buffer.  Thirty mg wet weight of mitochondrion (0.24 mg mitochondrial protein), 
thawed on ice, was suspended in 1 mL of mitochondrial-binding buffer, and then 
collected by centrifugation at 11,000 × g for 5 minutes.  Suspension and 
centrifugation steps were repeated twice.  The pellet was suspended in 1 mL of 
mitochondrial-binding buffer with added HKI (2 mg/mL), protease cocktail inhibitor 
(0.25mg/mL) and PMSF (1 mM).  After 60 minutes on ice, the mixture of HKI and 
mitochondria was centrifuged at 11,000 × g for 5 minutes.  Unbound HKI in the 
supernatant fluid was decanted.  Pelleted mitochondria were suspended in 
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mitochondrial-binding buffer, less the MgCl2, NaCl, and Glc, and centrifuged again.  
This wash step was twice-repeated. 
HKI-bound mitochondria, prepared as above, is suspended in release buffer 
(250 mM sucrose and 50 mM HEPES, pH 7.4).  100 µL aliquots of this suspension 
were distributed to plastic micro-centrifuge tubes, to which were added a release 
agent (ATP or TNP-nucleotide) at various concentrations.  After 30 minutes at room 
temperature, the mitochondria were pelleted by centrifugation.  HKI solubilized by 
nucleotide was removed by decanting the supernatant liquid.  The mitochondrial 
pellet was suspended in wash buffer (250 mM sucrose and 5 mM HEPES, pH 7.4), 
and centrifuged.  After discarding the supernatant fluid, pelleted mitochondria were 
suspended in 100 µL wash buffer and then assayed for hexokinase activity or 
suspended in 100 µL of coating buffer (100 mM sodium carbonate/bicarbonate, pH 
9.6) for ELISA assays. 
 HKI ELISA Assay— Fifty µL of HKI-bound mitochondrial suspension in 
coating buffer (100 mM Na2CO3/NaHCO3 pH 9.6) was loaded in each well of the 
ELISA plate and incubated overnight at 4 °C.  Plates were washed four times with 
PBST (137mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4, 1.76mM KH2PO4, pH 7.4, 0.05% 
Tween-20).  Wells were blocked with 200 µL of 1% BSA in PBST at room 
temperature for 2 hours and then washed four times with 200 µL PBST.  Wells were 
incubated with 100 µL of anti-His-tag primary antibodies (1:1000 dilution) for 2 
hours at room temperature, and then washed four times with PBST.  100 µL of anti-
rabbit IgG secondary antibodies solution (1:10000 dilution) was added to each well, 
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incubated for 2 hours at room temperature, and then washed four times with PBST.  A 
volume of 100 µL of 1-Step Ultra TMB-ELISA solution was added to each well.  A 
Biotek (Ceres 900) plate reader was used to measure change in absorbance at 
wavelength 620 nm.  A reading was taken every 10 seconds, a total of 75 for each 
well.  HKI was used as a positive control and mitochondria as a negative control.  
Slopes of linear progress curves were determined by regression analysis, and used in 
nonlinear least square fits (using GraFit) to models described in the Results section. 
 Mitochondria western blotting— Mitochondria with and without bound HKI 
were re-suspended in 15 µL water plus 3µL of loading buffer (1M Tris-HCl, pH 6.8, 
10% SDS, 3% glycerol, 0.12 mg/mL bromophenol blue) and boiled for 5 minutes 
prior to polyacrylamide gel electrophoresis (SDS-PAGE).  After removal of SDS, 
proteins were transferred by blotting from gel to nitrocellulose membranes (57). 
Membranes were blocked with 3% bovine serum albumin in 50 mM Tris, 150 mM 
NaCl, 0.05% Tween 20, pH 7.6, (TBST buffer) for one hour at room temperature and 
then washed three times with TBST buffer.  Membranes were exposed to primary 
antibody (His-Tag antibodies, C-terminal HKI antibodies, or N-terminal HKI 
antibodies) in TBST buffer for one hour at room temperature, and then washed three 
times with TBST buffer.  Membranes were subsequently treated with rabbit IgG 
secondary antibodies for one hour at room temperature and washed three times with 
TBST buffer.  Finally, x-ray film was exposed for 1 minute to membranes treated 
with Pierce chemiluminescence substrate and then developed. 
 Cloning of Wild-Type human VDAC-1— A plasmid with the coding sequence 
of human VDAC-1 was purchased from Open Biosystems.  NdeI and SacI cut sites 
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were created in the plasmid using the polymerase chain reaction (PCR) and NdeI 
primer 5'CGCGGCAGCCATATGATGGCTGTGCCACCCACG3' and SacI primer  
5'GGACTGGAATTTCAAGCA TCGAGCTCCGTCGACAAGC3'. The PCR product 
and vector pET-24a were digested by NdeI and SacI restriction enzymes.  After 
separation on agarose, the DNA fragment for human VDAC-1 was ligated to pET-24a.  
The construct was confirmed by DNA sequencing facility at Iowa State University. 
 Expression and Purification of Wild-Type human VDAC-1— Wild-type human 
VDAC-1 containing plasmid was transformed into E. coli strain BL21 (DE3).  Cells 
were grown in LB media at 37 °C, kanamycin was added to a final concentration of 
(30 µg/mL).  Growth was monitored by absorbance at wavelength 600 nm.  At A600 of 
0.9, the temperature was reduced to 16 °C and IPTG was added to a final 
concentration of 0.3 mM.  Cells were collected after 16-20 hours of induction and 
suspended in lysis buffer (30mM Tris-HCl, pH8.0, 150mM NaCl, 1mM EDTA, and 
1mM DTT).  DNase (50 µg/mL), leupeptin (5 µg/mL), and PMSF (1 mM) were all 
added to the solution. Cells were lysed by sonication.  Inclusion bodies were pelleted 
at 32460g for 1 hour.  Pelleted inclusion bodies were subjected to the following 
procedures three times: separation from the supernatant fraction, suspension in wash 
buffer (30 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) and 
centrifugation at 15,000 rpm 32460g for 30 minutes.  Inclusion bodies were 
suspended in 30 mL of wash buffer plus 1% Triton X-100, incubated for 30 minutes 
at 37 °C, and then suspended and washed twice with wash buffer. 
 Refolding of Wild-Type Human VDAC-1— HumanVDAC-1 purification and 
folding follows protocols in the literature (51, 58) with modifications.  Washed 
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inclusion bodies were solubilized in 150 mL dissolving buffer (6 M guanidine 
hydrochloride, 10 mM DTT, 0.1 mM EDTA, 100 mM Tris-HCl, pH8.0) to a final 
protein concentration of 15 mg/mL.  Inclusion bodies dissolved completely in 12 hr. 
at 4 °C.  Twenty five milliters of unfolded human VDAC-1were diluted by slow 
addition into 300 mL of refolding buffer (0.1 mM EDTA, 1 mM DTT, 100 mM Tris-
HCl, pH8.0, 2% LDAO) at 4 °C.  Refolded protein was concentrated and dialyzed 
against 50 mM Tris-HCl. pH 7.5, 0.1% LDAO buffer for 24 hr at 4 °C.  Solution was 
loaded onto a nickel-nitrilo triacetic acid (Ni2+-NTA) column.  The column was 
washed with buffers containing 50 mM Tris-HCl, pH7.5, 300 mM NaCl, 0.1% LDAO 
and 5 mM imidazole and then 50 mM imidazole.  Finally, human VDAC-1 was eluted 
with the same buffer containing 300 mM imidazole. 
 HKI and VDAC-1 Fluorescence Experiments— Purified HKI and human 
VDAC-1 were dialyzed against 2 mM glucose and 50 mM Tris-HCl, pH 7.5.  
Flurescence measurements were made at room temperature using a 1-cm2 quartz 
cuvette on a SLM Amico 8000 fluorometer with entrance/exit slits of 4 mm.  For 
TNP-nucleotides the excitation wavelength was 409 nm, and emission scans were 
from 450 to 600 nm.  Fluorescence scans (a total of three for each datum) were 
performed after additions of small volumes of TNP-nucleotide to 2 mL of 2.5 µM 
HKI or human VDAC-1.  TNP-nucleotide displacement was accomplished by the 
addition of the alternative nucleotide to 1 mL solution of 2 .5 µM HKI or human 
VDAC-1 and 1 µM TNP-nucleotide.  For each kind of experiment, the total 
concentration of added titrant did not exceed 5% of the initial volume of solution, and 
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the total concentration of titrant was corrected for volume changes.  The analysis of 
fluorescence data followed the approach of Fallar (59), modified as described in the 
Results section, using GraFit to perform nonlinear least squares fitting. 
Results 
 Mitochondria integrity and absence of native hexokinase— Cytochrome c 
oxidase activity indicated 90% integrity of OMM (data not shown).  Uptake of 
carbocyanine dye JC-1 indicated intact IMM (data not shown).  Western blotting of 
pig liver mitochondria and staining with polyclonal antibodies raised against HKI 
indicated the absence of native hexokinase (data not shown). 
 TNP-ADP inhibits HKI— Wild-type HKI (kcat = 73 ± 4 s-1, KmGlc = 77 ± 6 µM, 
KmATP = 1.1 ± 0.1 µM) exhibited no measurable activity with TNP-ADP as a 
replacement substrate for ATP, placing an upper limit on kcat of 0.001 s-1.  TNP-ADP 
has no effect on the activity glucose 6-phosphate dehydrogenase (coupling enzyme) 
up to a concentration of 100 µM. On the other hand, TNP-ADP is a competitive 
inhibitor with respect to ATP (Ki = 4.9 ± 0.5 µM) (Fig. 2.1). 
 TNP-nucleotide binding to Wild-type hexokinase I and displacement by ATP—
The observed fluorescence from a mixture of TNP-ADP and HKI comes from free 
TNP-ADP, TNP-ADP bound to HKI, and HKI itself:  
Fobs = Ffree + Fbound + Fprotein       Eq. 1 
Fprotein is small relative to other contributions as HKI has no native fluorophore 
sensitive to an excitation wavelength of 409 nm.  Ffree=a + b[L] +c[L]2, where a, b, 
and c are determined by a fit of fluorescence versus [L] in the absence of protein  
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 Fig. 2.1. TNP-ADP and ATP binding to WTHKI. TNP-ADP inhibition of HKI 
competitive with ATP HKI activity was measured using the Glc-6-P dehydrogenase 
assay in 100 mM Tris, pH 8.0, glucose 1.6 mM, ATP 0.3-4.5 mM and TNP-ADP 0 
µM (○), TNP-ADP 2.5 µM (●), TNP-ADP 5 µM (□), TNP-ADP 10 µM (■), TNP-
ADP 20 µM (∆), and TNP-ADP 40 µM (▲).  
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under buffer conditions identical to those used in the tritation of HKI.  Fbound = γb(Lo 
– [L]), where γ is a fluorescence enhancement factor of the bound relative to the free 
state of the fluorescent ligand and Lo and [L] are the total and free concentrations of 
fluorescent ligand. 
A single binding-site model adequately accounts for the observed fluorescence 
of the bound state and for the displacement of the TNP-nucleotide by a non-
fluorescent nucleotide: 
P + L = PL,  KL = [P][L]/[PL]  
P + A = PA,  KA = [P][A]/[PA]  
Scheme I 
In Scheme I, L represents the TNP-nucleotide and A the displacing ligand.  The 
equilibrium relationships of Scheme I with mass conservation relationships for Lo 
(total fluorophore concentration), Ao (total concentration of displacing ligand) and Po 
(total concentration of protein) leads to a third-order equation in the concentration of 
free protein [P].  For circumstances here, KA >> [P], allowing an approximation that 
reduces the third-order equation to one of second order: 
(1+ Ao/ KA)[P]2 + (KA – Po + Ao KL/KA + Lo)[P] – PoKL = 0   Eq. 2 
The physical root of this quadratic relationship is the concentration of free protein, 
and determines the concentration of free fluorophore [L] = LoKL/(KL+[P]) at a given 
total concentration of fluorophore, Lo.  GraFit software optimizes the fit of the 
observed fluorescence to the right-hand side of Eq. 1 at fixed Po and varying Lo and 
Ao by adjusting parameters KA, KL, γ and Fprotein.  TNP-ADP binds to wild-type HKI  
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with high affinity (KL = 0.79 ± 0.09 µM, γ = 14.8 ± 0.3, and Fprotein = 0.017 ± 0.002) 
and weakly to the N-domain of HKI (KL = 900 ± 800 µM) (Fig. 2.2).  ATP displaces 
TNP-ADP from wild-type hexokinase (KA = 190 ± 20 µM) (Fig. 2.3). 
 TNP-nucleotide binding to wild-type human VDAC-1 and displacement by 
nucleotides— Single binding site model of Scheme I also account for TNP-ADP 
binding to VDAC-1 and its displacement by ATP.  Analog TNP-ADP binds to VDAC-
1 with high affinity (KL = 1.3 ± 0.1 µM, γ = 16.7 ± 0.3, Fprotein = 0.06 ± 0.02) (Fig. 2.4) 
and is displaced by ATP (KA = 550 ± 40 µM) (Fig. 2.5).  CDP does not displace TNP-
ADP from VDAC-1 (Fig. 2.6).  Analogs TNP-ATP, TNP-AMP and TNP-CTP bind to 
VDAC-1 similarly to TNP-ADP (Table 2.1). 
Nucleotide release of wild-type HKI— Incubation times of twenty and sixty minutes 
produced identical release curves, indicating an equilibrium phenomenon.  Scheme II 
represents the simplest equilibrium model that accounts for ATP-release of wild-type 
and mutant enzymes from mitochondria. 
E + Q = EQ,  K1 = [EQ]/[E][Q] 
E  + P = EP  K2 = [EP]/[E][P] 
Q + A = QA  K3 = [QA]/[Q][A] 
         Scheme II 
In Scheme II, K1 and K2 represent association constants for the binding of HKI 
(represented by E) to specific mitochondrial binding sites Q, and nonspecifically to 
the membrane at sites P.  The association constant K3 represents the binding of A 
competitively with E for the specific binding sites Q.  The fraction of E bound to  
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 Fig. 2.2.  Titration of HKI constructs with TNP-ADP.  Plots represent the 
fluorescence at varying total concentrations of TNP-ADP in 2 mM glucose and 50 
mM Tris-HCl, pH 7.5, with no protein (▲), wild-type HKI 2.5 µM (●), and N-
domain HKI 2.5 µM (○).  Black lines for wild-type and N-domain HKI represent Eq. 
1 with Ao of 0 µM, Po of 2.5 µM and parameters KL, KA, γ and Fprotein given in the 
Results section.  The gray line is the fit of observed fluorescence in the absence of 
protein to the second-order polynomial, a + b(Lo) + c(Lo)2. 
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 Fig. 2.3.  Titration of wild-type HKI bound TNP-ADP with ATP.  Plot 
represents the fluorescence at varying total concentrations of ATP (○) added to 2.5 
µM wild-type HKI and 5 µM TNP-ATP in 2mM glucose and 50 mM Tris pH 7.5.  
The solid line represents is a fitted curve using Eq. 1 with Lo of 5 µM, Po of 2.5 µM 
and parameters KL, KA, γ and Fprotein given in the Results section. 
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 Fig. 2.4.  Titration of wild-type human VDAC-1 with TNP-ADP.  Plots 
represent the fluorescence at varying total concentrations of TNP-ADP in 2 mM 
glucose and 50 mM Tris-HCl, pH 7.5, with no protein (▲) or with wild-type human 
VDAC-1 2.0 µM (●).  The black line represents Eq.1 with Po of 2 µM, Ao of 0 µM 
and parameters KL, KA, γ and Fprotein given in the Results section.  The gray line is the 
fit of observed fluorescence in the absence of protein to the second-order polynomial, 
a + b(Lo) + c(Lo)2. 
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 Fig. 2.5.  Titration of wild-type human VDAC-1 bound TNP-ADP with ATP.  
Plot represents the fluorescence at varying total concentrations of ATP (○) added to 
2.0 µM wild-type human VDAC-1 and 5 µM TNP-ATP in 2mM glucose and 50 mM 
Tris, pH 7.5.  The black line represents Eq. 1 with Po of 2 µM, Lo of 5 µM and 
parameters KL, KA, γ and Fprotein given in the Results section. 
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 Fig. 2.6.  Human VDAC-1 bound TNP-ADP displacement by nucleotides. 
Fluorescence scans of 2.0 µM human VDAC-1 in 2mM glucose and 50 mM Tris, pH 
7.5.  human VDAC-1 only (○), 5 µM TNP-ADP only (○), human VDAC-1 plus 5 µM 
TNP-ADP (●), human VDAC-1 plus 5 µM TNP-ADP and 10 mM ATP (▲), and 
human VDAC-1 plus 5 µM TNP-ADP and 10 mM CDP (▲). 
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Table 2.1.  TNP-nucleotides binding to wild-type human VDAC-1. 
TNP-nucleotide KL (µM) γ Fprotein 
TNP-ATP 0.5 (2) 16.4 (9) 0.40 (9) 
TNP-ADP 1.3 (1) 16.7 (3) 0.06 (2) 
TNP-AMP 2.0 (1) 20.4 (3) 0.13 (2) 
TNP-CTP 0.7 (1) 11.2 (3) 0.22 (2) 
Parameters are from a single binding site model.  KL, γ and Fprotein are constants for the 
dissociation of TNP-nucleotides from human VDAC-1.  Fluorescence was measured at 
varying total concentrations of TNP-nucleotides in 2 mM glucose and 50 mM Tris-HCl, 
pH 7.5.  Standard deviations in the last significant digits are given in parentheses. 
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mitochondria depends explicitly on the concentrations of Q and P, and implicitly on 
the concentration of A as follows: 
   R([A]) = (K1[Q] + K2[P])/(1+K1[Q]+K2[P]) = (K1[Q] + K2′)/(1+K1[Q]+K2′)     Eq. 3 
The concentration of free nonspecific binding sites for hexokinase is overwhelmingly 
large allowing a pseudo constant K2′ to approximate the product K2[P].  The 
concentration of free specific mitochondrial sites Q is itself a function of the 
concentrations of enzyme and competitive binding ligand.  Algebraic manipulation of 
the equilibrium expression in Scheme II and relationships for mass conservation of 
total enzyme Eo and total specific sites Qo results in a quadratic relationship in Q: 
a[Q]2 + b[Q] + c = 0 
where a = K1(1+K3[A]), b = K1(Eo–Qo)+(1+K2′)(1+K3[A]), and c = –Qo(1+K2′).  The 
general solution to the quadratic equation gives [Q]: 
 [Q] = –{K1(Eo–Qo)+(1+K2′)(1+K3[A])}/{2K1(1+K3[A])} 
+{K12(Eo–Qo)2+2K1(Eo+Qo)+(1+K2′)(1+K3[A]) 
+(1+K2′)2(1+K3[A])2}1/2/{2K1(1+K3[A])}    Eq. 4 
Substitution of Eq. 4 into Eq. 3 provides a relationship for the fraction of enzyme 
bound to the mitochondria R([A]), explicitly as a function of [A]. 
The fitting relationship is V = sR([A]) (Eq. 5), where s is a proportionality constant 
that relates the fraction of bound enzyme R([A]) to velocity V in µmoles/min.  Eq. 5 
includes undefined quantities s, Eo, Qo, K1, K2′ and K3; all six cannot be determined 
by a nonlinear least squares fit of data from a single experiment.  Hence, values for 
some of these quantities must come from other determinations.  Firstly, one assumes 
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the HKI-VDAC complex has an equal number of HKI and VDAC subunits.  The 
value for Qo (7.1x10–8 M) then is an estimate based on 42,000 VDAC molecules per 
mitochondrion (60), 7.2x109 mitochodria per 1 mg of total mitochondrial protein (61), 
and 0.014 mg of mitochondria in each 100 µL assay.  In binding HKI to mitochondria, 
the concentration of enzyme (10-6 M) is 10-fold greater than the estimated 
concentration of specific binding sites.  After washing away excess enzyme, we 
assume all specific sites have bound enzyme, and that the condition Eo=Qo applies to 
the system.  The release of HKI is complete at the highest levels of nucleotide, 
R([A]→∞) = 0, which requires K2′ = 0.  Moreover, s = Qo×(specific activity)×(assay 
volume), where the specific activity for HKI is 6x109 µmole/min-1 mole-1 and the 
assay volume is liters.  Hence, if the assumption of a 1:1 ratio of the HKI-VDAC 
complex is correct, then data can be fit to Eq. 5 using K1 and K3 alone as adjustable 
parameters.  Moreover, as K1 represents the binding affinity of HKI for the 
mitochondrion, all experiments using wild-type HKI should provide comparable 
values for K1 regardless of the release agent.  Listed in Table 2.2 are values for K1 and 
K3 for 8 release experiments involving ATP and ADP.  Although correlations in K1 
and K3 are evident, one finds values of K1 within a single order with an average value 
of 4.1 ± 1.0x108 M-1.  In release experiments involving the HKI activity assay, K1 is 
set to its average value, and only K3 is optimized in fitting the data.  The true 
uncertainty in K3 then is on par with that for the average value of K1; however, on a 
comparative basis the K3 values in Table 2.3 accurately reflect the relative binding 
efficacies of nucleotides to VDAC.  Characteristic release curves are in Fig. 2.7.  All 
TNP-nucleotides tested were effective in the release of wild-type HKI from  
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Table 2.2. ATP and ADP release of wild-type HKI from pig liver mitochondria in the 
determination of K1. 
 K1 (M-1) K3ATP (M-1) K3ADP (M-1) 
Experiment 1 6.0 x 108 (1.2 x 108) 5.2 x 104 (1.7 x 104) - 
Experiment 2 5.1 x 108 (7.8 x 107) 4.9 x 104 (8.9 x 103) - 
Experiment 3 6.6 x 108 (2.4 x 108) 1.5 x 104 (6.1 x 104) - 
Experiment 4 8.1 x 108 (3.3 x 108) 1.7 x 105 (7.7 x 104)  
Experiment 5 1.3 x 108 (1.5 x 107) 3.6 x 104 (6.7 x 103)  
Experiment 6 1.2 x 108 (1.3 x 107) 3.7 x 104 (6.6 x 103)  
Experiment 7 2.7 x 108 (6.9 x 107) - 9.6 x 103 (3.7 x 103) 
Experiment 8 2.1 x 108 (4.4 x 107) - 8.5 x  103 (2.6 x  103) 
Parameters are from an equilibrium model in which the binding of nucleotide and 
WHKI and nucleotide to the mitochondrion is mutually exclusive. K1, K3ATP and 
K3ADP are constants for the association in M-1 of HKI, ATP and ADP from the 
mitochondrion. Mitochondria with HKI bound in 250mM sucrose and 50 mM HEPES, 
pH7.5, were exposed to different nucleotides for 30 minutes. Remaining 
mitochondria bound HKI was measured by activity. Standard eviations in the last 
significant digits are given in parentheses. 
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Table 2.3. Release of wild-type HKI from pig liver mitochondria by TNP-nucleotides. 
TNP-nucleotide K3 (M-1) 
ATP 9.9 x 104 (3.0 x 103) 
ADP 1.8 x 104 (3.5 x 103) 
TNP-ATP 2.7 x 105 (2.7 x 104) 
TNP-ADP 3.7 x 105 (5.2 x 104) 
TNP-AMP 3.1 x 105 (5.2 x 104) 
TNP-CTP 1.9 x 105 (4.8 x 104) 
Parameters are defined in the Results section and by Scheme II.  K1 is set to its 
average value of 4.1x108 M-1 and K3 determined by fitting Eq. 5 to data as described 
in the Results section.  Standard deviations in the last significant digit are given in 
parentheses 
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 Fig. 2.7.  Nucleotide-induced release of wild-type HKI from pig liver 
mitochondria.  Mitochondria with HKI bound in 250 mM sucrose and 50 mM HEPES, 
pH 7.5, were exposed to different nucleotides for 30 minutes.  Plots represent relative 
velocities from mitochondria-bound HKI that remains after exposure to varying 
concentrations of ATP (▲), TNP-ATP (○), or TNP-ADP (●).  The solid lines 
represent fitted curves using Eq. 5 with parameters given in the Results section and 
Table 2.3. 
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mitochondria. 
Nucleotide induced release of N-domain HKI from mitochondria— Validation 
of the ELISA assay is provided by Fig. 2.8.  Release of wild-type HKI, determined as 
a percent of total release, is measured comparably by the ELISA and the HKI activity  
assays.  Measures of nucleotide affinity constants come from the fitting data to Eq. 5.  
The parameter s, however, is difficult to determine, requiring the optical path length 
of a plate reader, and the assumption of one to one correspondences between the 
hexokinase construct, primary antibody, and secondary antibody/peroxidase 
components.  Moreover, nonzero background levels in the presence of high 
concentrations of nucleotide require a nonzero K2′.  Hence, fitting of data from 
ELISA assays employs s, K2′ and K3 as parameters.  TNP-ADP and ATP release wild-
type HKI and N-domain HKI from mitochondria to a comparable extent (Fig. 2.8), 
and provide values for K3 that compare favorably to those of the determined from the 
HKI assays (Table 2.4). 
Discussion 
 Previous reports demonstrated the release of HKI from mitochondria by ATP 
and other nucleotides at millimolar concentrations (16, 45-47).  The importance of the 
hexokinase-mitochondrion interaction to apoptosis motivated our efforts to quantify 
and determine the mechanism of nucleotide release of HKI from mitochondria.  Four 
general mechanisms can account for ATP-release of HKI from mitochondria (Fig. 
2.9): ATP binds to the C-terminal domain of HKI causing release.  ATP and HKI bind 
with mutual exclusion to human VDAC-1.  ATP binds to the N-terminal domain of  
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 Fig. 2.8. Nucleotides induced release of wild-type HKI and N-domain HKI 
from pig liver mitochondria measured by kinetic ELISA.  Mitochondria with HKI 
bound in 250 mM sucrose and 50 mM HEPES, pH 7.5, were exposed to different 
nucleotides for 30 minutes.  Plots represent wild-type HKI (●) or N-domain HKI (○) 
that remains bound to mitochondria as measured by His-TAG antibodies and ELISA. 
The solid lines represent fitted curves using Eq. 5 with parameters given in the 
Results section and Table 2.4. 
 
 
 
  
 
 
Table 2.4.  Nucleotide-dependent release of HKI constructs from pig-liver mitochondria. 
HKI Construct Nucleotide s (µmol/min) K2′ (M-1) K3 (M-1) 
Wild-typea ATP 0.0213* 0** 3.1 x 104 (2.9 x 103) 
 TNP-ADP 0.0213* 0** 2.3 x 105 (6.8 x 104) 
Wild-typeb ATP 0.098 (3) 0.14 (3) 1.3 x 104 (8.2 x 103) 
 TNP-ADP 0.110 (1) 0.24 (1) 1.8 x 105 (3.8 x 104) 
N-domainb ATP 0.190 (2) 0.44 (2) 2.8 x 104 (5.9 x 103) 
 TNP-ADP 0.069 (1) 0.73 (2) 1.3 x 105 (4.1 x 104) 
Parameters are defined in the Results section and by Scheme II. K1 is set to its average value 4.1x108 M-1 and s, K2' and K3 
determined by fitting to Eq.5 to data as described in the Results section. Mitochondria with HKI bound in 250 mM sucrose 
and 50 mM HEPES, pH 7.5, were exposed to different nucleotides for 30 minutes. Remaining mitochondria bound HKI 
was measured by activity and/or ELISA.  Standard deviations in the last significant digit are in parentheses. 
aMeasured by HKI activity 
bMeasured by His-tag antibodies and kinetic-ELISA 
* Calculated as described in the Results section 
** Fixed at zero as described in the Results sectio
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 Fig. 2.9.  Four mechanisms by which ATP could release HKI from 
mitochondria.  VDAC-1 (cylinder) HKI (rectangles) interact directly.  ATP binds to 
HKI, C-terminal half, (Mechanism I), to VDAC (Mechanism II), or to HKI, N-
terminal half (Mechanism III) to disrupt the HKI-VDAC-1 complex.  HKI produces 
glucose 6-phosphate from ATP, which in turn binds to N-terminal half of HKI 
(Mechanism VI) to disrupt the HKI-VDAC-1 complex. 
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HKI causing release.  HKI converts ATP and glucose to Glc-6-P, which in turn binds 
to the N-terminal half of HKI triggering release. 
 The experimental protocols adopted here avoid the combination of glucose 
and ATP, which in the presence of Mg2+ and HKI would result in the generation of 
Glc-6-P.  TNP-nucleotides are not substrates for HKI (current study) or for yeast 
hexokinase (62).  TNP-ADP binds to HKI and yeast hexokinase at micromolar 
concentrations and is displaced by ATP.  In the absence of Mg2+ both TNP-ADP and 
ATP release HKI from mitochondria.  Under such conditions, the evolution of Glc-6-
P from ATP and glucose is an unlikely cause for ATP release, and cannot be the 
mechanism by which TNP-ADP releases HKI from the mitochondrion (Mechanism 
IV). 
A test of Mechanisms II and III requires an assay for N-domain HKI, which 
has no hexokinase activity.  Data of Fig. 2.10 validate the kinetic ELISA assay to 
measure levels of N-domain HKI bound to mitochondria.  The kinetic ELISA 
measures the HKI construct in any state (active or inactive), whereas the HKI activity 
assay measures only HKI in an active state.  The presence of substantial peroxidase 
activity in the presence of high levels of nucleotide indicates residual HKI bound to 
the mitochondrion.  This bound fraction of HKI must not be active, as it would be 
detected by the HKI activity assay.  Blank samples (mitochondria not exposed to an 
HKI construct) in the ELISA assay have low peroxidase activity, consistent with 
Western blots which indicate no bound HKI on the surface of the pig-liver 
mitochondria.  Released HKI, as a fraction of total released HKI, is nonetheless in 
excellent agreement for the two assay methods (Fig. 2.10). 
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 Fig. 2.10.  Nucleotide release of wild-type HKI and N-domain HKI from pig 
liver mitochondria.  Plots represent wild-type HKI (■) remained bound to 
mitochondria and measured by activity and N-domain HKI (□) remained bound to 
mitochondria and measured by His-tag antibodies and ELISA.  
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Release of HKI and N-domain HKI are indistinguishable by the kinetic 
ELISA assay (Fig. 2.8).  Evidently, the C-terminal half of HKI plays no significant 
role in the binding of HKI to the mitochondrion.  Indeed, other evidence is consistent 
with this view.  Polyclonal antibodies directed to the C-terminal half of HKI do not 
release HKI from mitochondria, whereas antibodies directed toward the N-terminal 
half of HKI cause release (63).  Mutations to the Glc-6-P binding site at the N-
terminal half greatly diminish release of HKI by Glc-6-P, but mutation to the Glc-6-P 
site at the C-terminal half has little effect on release (44).  The indistinguishable 
release of HKI and N-domain-HKI but ATP and TNP-ADP is inconsistent with 
Mechanism I, which attributes release to nucleotide association with the C-terminal 
half of HKI. 
A single-site binding model accounts for TNP-ADP association with HKI.  
That binding site is not part of the N-terminal half, as TNP-ADP binds weakly to N-
domain HKI.  Potent competitive inhibitor of TNP-ADP with respect to ATP is 
consistent with a high-affinity site at or near the active site of the C-terminal half.  
TNP-ADP does not bind to N-domain HKI and yet releases N-domain HKI from 
mitochondria, observations clearly inconsistent with Mechanism III. 
Although it is relatively straightforward to exclude mechanisms of release, to 
actually prove the remaining mechanism (Mechanism IV) requires the accumulation 
of overwhelming experimental evidence.  The approach here is to demonstrate 
correlations between nucleotide release of HKI from mitochondria and high-affinity 
binding to human VDAC-1.  In fact if Mechanism IV is correct, newly-discovered 
agents that bind to human VDAC-1 competitively with respect to TNP-ADP should 
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also release HKI from mitochondria.  The TNP-nucleotides (TNP-ATP, TNP-ADP, 
TNP-AMP, and TNP-CTP) bind to human VDAC-1 with high affinity (Table 2.1), 
and each is effective in the release of HKI from the mitochondrion (Table 2.3).  The 
affinity of TNP-nucleotides to the mitochondrion, as measure by the release 
experiments (K3) and by fluorescence titrations (KL) are in reasonable agreement.  
Moreover, CDP does not displace TNP-ADP from human VDAC-1, and is not 
effective as a release agent (Figs. 2.6 & 2.10).  These findings are consistent with 
Mechanism IV.  If the target protein is not VDAC, then it must be another protein of 
equal abundance, able to bind TNP-nucleotides with similar high affinities, but not 
CDP.  As VDAC is reportedly the most abundant protein in the outer leaflet, another 
protein with these attributes seems a remote possibility. 
One should note, however, an apparent discrepancy within the body of data 
presented here.  Firstly, 1/K3 for ATP release of HKI is ~5x10-5 M, whereas KA for 
ATP measured by fluorescence is ~5x10-4 M.  The basis for this difference is unclear.  
Mg2+ is necessary for the association of HKI with mitochondria, and quite possibly 
ATP releases HKI not only through its interaction with VDAC, but also by chelation 
of Mg2+.  ATP and ADP, however, are nearly equal in efficacy of HKI release.  
Moreover, release of HKI by TNP-nucleotides show no dependence on the number of 
phosphoryl groups, release efficacies and binding affinities being linked to the 
trinitrophenol functionality.  Although TNP-ADP does not bind to the N-terminal half 
of HKI, one cannot rule-out a release effect due to the binding of ATP (or ADP) to the 
N-terminal half.  Mutations of residues at the ATP binding site of the N-terminal half, 
however, seem not to influence ATP release (Skaff, Honzatko, and Fromm, 
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unpublished).  ATP could bind to an additional site on VDAC which does not exclude 
the binding of TNP-ADP.  An azido photoaffinity label modifies VDAC at three 
positions that could map to distinct sites (50). 
Although the focus here is on a mechanism of release, one can glean some 
basic understanding of the subunit stoichiometries in the HKI-VDAC-1 complex.  
Firstly, the ratio of HKI to VDAC must be at least one to one.  If HKI is present at 
ratios less than unity with VDAC, then the observed reaction velocities in the absence 
of release agent are unachievable.  A ratio of 1:2 HKI to VDAC requires a doubling of 
the estimated number of VDAC molecules in the mitochondrion.  HKI forms dimers 
(15,48), and at least one report in the literature indicates a subunit tetramer of 
mitochondrion-bound hexokinase (64).  An assumption of 4:1 HKI to VDAC for 
release data presented here decrease K1 by 20-fold (~107 M-1) and K3 by 4-fold, but 
the relative values of K3 remain unchanged.  Hence, the affinity constants presented 
here are fairly insensitive to radical departures from the assumed 1:1 subunit ratio of 
the HKI-VDAC complex. 
Multimers of mitochondrion-bond HKI, to the extent that they form, must not 
involve interactions of C-terminal halves to be consistent with observations here.  In 
fact, the simplest structural model consistent with release data is complex involving 
the N-terminal half of HKI with VDAC.  Using the X-ray structure of mouse VDAC-
1 (65), the N-terminal hydrophobic tail of HKI most likely interacts with lipid and the 
external surface of the VDAC β-barrel.  TNP-ADP, however, is highly anionic, 
having at pH 7.5 formal charges on the phosphoryl and nitro groups.  The most 
probably binding site for this anion is somewhere at the inner surface of the VDAC 
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barrel, which is lined with positively charged side chains.  The model here is one of 
completion between TNP-ADP and HKI for VDAC, and leaves two possibilities: 
Either the binding of TNP-ADP cause such significant conformational change in 
VDAC as to disrupt interactions involving the N-terminal resides of HKI or another 
set of surfaces residues of the N-terminal half of HKI are essential to the stability of 
the HKI-VDAC complex. 
Disruption of the hexokinase-mitochondrion association is the intention of 
potential anti cancer drugs (66).  Hexokinases I&II are often over-expressed in cancer 
cell lines, presumably to block pro-apoptotic signals which act through the release of 
cytochrome c from the mitochondrion.  Remove hexokinase from the mitochondrion, 
and cancer cell succumb to apoptosis or have heightened sensitivity to existing 
treatments for cancer.  Small molecules such as clotrimazole, bifonazole (67), 3-
bromopyruvate (68) and methyl jasmonate (69) dissociate hexokinase from the 
mitochondrion.  In most cases, the mechanism of release has not been determined, as 
has been here for the TNP-nucleotides and for Glc-6-P (44).  VDAC evidently is a 
target for small molecules that release mitochondrion-bound hexokinase.  As the 
trinitrophenol group seems critical to binding affinity and not the phosphoryl groups 
or nucleotide base, one has a reasonable expectation of finding a molecule of high 
specificity and within the parameters that define substances of potential 
pharmacological value. 
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CHAPTER 3: SINGLE-RESIDUE DETERMINANTS IN THE 
BINDING OF RECOMBINANT HUMAN BRAIN HEXOKINASE 
TO THE MITOCHONDRION14 
A paper to be submitted to the Journal of Biological Chemistry 
Nimer Mehyar2, Nidhi Shah, Lu Shen, Dong Yan, and Richard B. Honzatko2,35 
 
Abstract 
 The N-terminal segment (residues 1-15) of hexokinase I (HKI) is essential for 
the binding of HKI to the outer membrane of the mitochondrion.  Whether the N-
terminal segment is merely a hydrophobic anchor to the membrane or has specific 
residues that are key determinants in the mitochondrion-HKI interaction is unclear.  
Recombinant wild-type HKI binds to mitochondria, but the removal of residues 1-15 
abolishes such binding.  Mutations A4L, A8L and Q5P individually cause a 10-fold 
decreases (relative to wild-type enzyme) in HKI binding to mitochondria.  In contrast, 
mutations Q5A, Y10L and T12I decrease binding by approximately twofold.  The 
mutations did not affect the catalytic properties of the enzyme, and all HKI constructs 
remained monomeric to concentrations as high as 10 micomolar.  Results here are 
consistent with a helical conformation for the N-terminus of HKI, with residues A4 
                                                 
1This research was supported in part by National Institute of Health Research Grant 
NS 10546 
3To whom correspondence should be addressed. 
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and A8 defining a contiguous surface that does not tolerate large hydrophobic side 
chains. 
Introduction 
 Hexokinases catalyze glucose phosphorylation by adenosine tri-phosphate 
(ATP) to produce glucose 6-phosphate (Glc-6-P).  Mammals have four isozymes of 
hexokinase: I, II, III and IV (1).  Hexokinase I (HKI) or brain hexokinase regulates 
glucose metabolism in brain tissue and the red blood cell (2).  Hexokinases (I-III) 
have molecular masses of approximately 100 kDa (1), consisting of C- and N-
terminal halves with significant levels of sequence identity to each other and to yeast 
hexokinase (3).  Hexokinase IV (glucokinase) is a 50 kDa protein with a sequence 
similar to both C-terminal and N-terminal halves of hexokinase I-III and to yeast 
hexokinase (4).  Similarities between mammalian isoenzymes evidently originate 
from the duplication and fusion of a primodial hexokinase gene similar to that of 
yeast hexokinase (5).  A number of ligands inhibit HKI; however, Glc-6-P is probably 
the primary physiological inhibitor of the type-I enzyme (6).  Glc-6-P inhibits HKI 
catalysis by binding with high affinity to either the C- or N-terminal halves (7,8). 
Under normal physiological conditions, inorganic orthophosphate (Pi) decreases Glc-
6-P inhibition (9).  Pi binds tightly to the N-terminal half of HKI and relieves Glc-6-P 
inhibition by an allosteric mechanism that couples both halves of the enzyme (10) 
(11).  At elevated levels, Pi inhibits HKI by binding to the active site (12). 
Despite structural similarities, hexokinases (I-III) are functionally different. 
Both halves of HKII support catalysis and are each sensitive to inhibition by Glc-6-P 
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(13), whereas only the C-terminal half of HKI and HKIII supports activity (14,15). 
Nonetheless, Pi can relieve Glc-6-P inhibition of HKI alone (4,7-8,12). 
HKI co-localizes on the outer mitochondrial membrane (OMM) in brain tissue 
preferentially close to newly formed ATP inside the mitochondrion (16,17).  In tumor 
cells, mitochondrion-associated HKII antagonizes Bax-induced cytochrome c release 
and in turn inhibits apoptosis (18-20).  Bax interacts with permeability transition pore 
(PTP) resulting in loss of membrane potential, triggering of mitochondrial membrane 
permeabilization (MPP) and release of cytochrome c (21).  Pro-apoptotic proteins 
such as Bax, Bak, and Bim interact with voltage-dependent anion channel (VDAC) 
forming an assembly of large channels likely used for cytochrome c passage from 
mitochondrion matrix to cytoplasm (22-24).  VDAC is part of PTP, which in addition 
to VDAC, includes the adenylate translocator (ANT) of the inner mitochondrion 
membrane (IMM) (25-29), and cyclophilin D of the inner mitochondrion matrix (30-
32).  Released cytochrome c activates the caspase family of proteases in cytoplasm, 
which in turn triggers apoptosis (32-34).  VDAC-1 overexpression causes apoptotic 
cell death (35,36).  Hexokinase I and II, in association with VDAC, likely antagonize 
the formation of apoptotic channels.  Some have gone so far as to label hexokinase as 
“guardian of the mitochondria” (37). 
Over expression of N-terminally truncated VDAC-1 did not induce cells to 
release cytochorme c, and such cells were resistant to apoptosis (38).  N-terminus 
peptide and other VDAC-1 based peptides bind to immobilized HKI, these peptides 
prevent HKI-protection of cells (39).  Chemical modification of Glu 72 prevents HKI 
from binding to mitochondria (35).  Mutating Glu 72 and other residues abolishes 
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HKI-protection against apoptosis in cancer cells (40).  Adding HKI to VDAC-1 
reconstituted in lipid membrane reduced the channel conductance (25); however, the 
addition of HKI to mutant mouse VDAC-1 E72Q reconstituted in lipid membrane did 
not block conductance in patch clamp experiments, indicating failure of HKI to bind 
to mutant VDAC-1 (40). 
A number of small and physiological important ligands are capable of 
dissociating HKI from the mitochondrial outer membrane.  These compounds include 
Glc-6-P and ATP (16).  Skaff et al. (41) demonstrated wild-type recombinant HKI 
with properties comparable to native brain hexokinase including those of 
mitochondrial-binding and release.  The recombinant construct has an intact 
membrane targeting element and a formyl group attached to the amino terminus of the 
polypeptide chain.  The release properties of mutant constructs demonstrated the 
significance of Glc-6-P binding to the N-terminal half of HKI in promoting the 
release of the mitochondrion-associated enzyme.  Nucleotide-induced release, on the 
other hand, follows a competitive binding model between HKI and nucleotides a 
binding site on VDAC1 (unpublished data). 
Early studies showed that digesting hexokinase I with proteases resulted in 
loss of mitochondrial binding properties (16).  Rapid purification of rat brain 
hexokinase using HPLC decreased the portion of HKI devoid of mitochondria-
binding properties (42,43).  Rat-brain hexokinase with mitochondrion-binding 
properties intact is more hydrophobic than the non-bindable form (44).  The two 
enzyme forms (with and without mitochondrial binding properties) have similar 
molecular weights and kinetic properties (45).  N-terminal sequence of rat brain 
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hexokinase was determined as a critical determinant of mitochondrial binding of HKI 
(46).  The N-terminus of HKI from native tissue is putatively blocked by an acetyl 
group (47).  Xie and Wilson (1988) proposed a helical conformation of the first 11 
residues of HKI N-terminus.  This conformation allows the insertion of the N-
terminus in a lipid bilayer (46,48).  The effect of monoclonal antibodies against rat 
brain hexokinase varied from blocking mitochondrial binding to inhibiting Glc-6-P 
release (49).  Mitochondrial-bound rat brain hexokinase was released upon exposure 
to monoclonal antibodies raised against the N-terminus (50). 
Although some studies stress that hexokinase binding to mitochondria is 
determined by the hydrophobicity of the tail (51,52), HKI cellular co-localization 
with VDAC on OMM (17) implies more complex and specific interactions than 
general hydrophobic interactions with lipid.  To date, no single residue has been 
proven essential to hexokinase association with the mitochondrion.  Yet inspection of 
the putative N-terminal helix of HKI reveals amino acids with small side chains 
localize to only one face of the helix, whereas large side chains occupy all other faces.  
Does the helix surface defined by small side chains make critical contacts with a 
protein binding partner (presumably VDAC) in the outer  membrane of the 
mitochondria?  Indeed, the mutation of Ala 4 and Ala 8 to leucine abolished 
hexokinase association with the mitochondrion, whereas mutations at other residues 
have little or no effect.  The discovery of a localized surface critical to hexokinase 
association with the mitochondrion provides a useful constraint in modeling possible 
HKI-VDAC complexes. 
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Experimental Procedures 
 Materials—ATP, Glc-6-P, ampicillin, deoxyribonuclease (DNase I), bovine 
serum albumin (BSA), leupeptin, protease cocktail inhibitor and 
phenylmethylsulfonyl fluoride (PMSF) came from Sigma.  DEAE HPLC resin was a 
product of Tosohaas. E.coli strain BL21 (DE3) competent cells were from Novagen.  
Glucose-6-phosphate dehydrogenase was obtained from Roche Molecular 
Biochemicals.  Isopropyl-1-thio-β-D-galactopyranoside (IPTG) came from Anatrace. 
Sequencing PVDF membranes (ProSorb sample preparation cartridge) were 
purchased from Applied Biosystems. 
 Construction of Wild-type Hexokinase and Mutant Plasmids—Human brain 
hexokinase (HKI) had been cloned into pET-11a as reported in a previous study (41).  
Hexokinase mutants were created through PCR modification with oligonucleotide 
primers synthesized at the Iowa State University DNA Sequencing and Synthesis 
Facility.  Mutants Ala4Leu, Ala8Leu, Thr12Ile, Gln5Ala and Gln5Pro were created 
with the following forward primers (and their reverse compliments) respectively: 
5'CATATGATCGCCCTGCAGCTCCTGGCC-3'; 
5'CGCAGCTCCTGCTCTATTACTTCACGGAGC-3'; 
5'GCCTATTACTTCATTGAGCTGAAGGATG-3'; 
5'GATCGCCGCGGCGCTCCTGGCC-3'; 
5'GATCGCCGCGCCGCTCCTGGCC-3'. 
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Iowa State University DNA Sequencing and Synthesis Facility confirmed all final 
constructs by sequencing the DNA of the entire gene. Mutant Y10L was used in 
previous studies (unpublished data). 
 Expression and Purification of Wild-Type and Mutant Hexokinases— Wild-
type or mutant pET-211a-HKI plasmids were transformed into E.coli strain BL21 
(DE3).  Expression and purification of HKI enzymes were previously discussed (41).  
Protein concentrations employed the Bradford method with bovine serum albumin as 
a standard (53). 
 Pig Liver Mitochondria Purification— Pig livers were obtained from the Iowa 
State University Meats Laboratory shortly after slaughter.  Mitochondrial purification 
is described (54) with modifications as discussed elsewhere (41).  Both outer 
mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM) 
integrities were measured as described previously (55, 56).  Mitochondria were stored 
at –80º C in the presence of 5% dimethyl sulfoxide. 
 The HKI Activity Assay— Hexokinase activity was measured using the 
glucose 6-phosphate dehydrogenase (G6PDH)-coupled spectrophotometric assay.  
Assay solutions have 3mM MgCl2, 3 mM DTT, 0.3 mM NADP and 10 µg/mL 
G6PDH in 50 mM Tris-HCl, pH 8.0, and concentrations of glucose and ATP:Mg2+ 
that varied from 1/5 x Km to 5 x Km.  NADPH production was monitored at 340 nm 
wavelength.  Reaction was initiated by the addition of enzyme and linear progress 
curves monitored for 3 minutes.  Slopes were used to calculate initial rates in 
umole/min.  The capacity of the coupling enzymes was verified by observing a 
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twofold increase in velocity with a doubling of added hexokinase.  Initial rate data 
were analyzed using GraFit (57). 
 Mitochondrial Binding and Release— Purified HKI was dialyzed twice 
against mitochondrial-binding buffer (250 mM sucrose, 5 mM Glc, 50 mM NaCl, 5 
mM MgCl2 and 50 mM HEPES, pH 7.4), and then diluted to 2 mg/mL using the same 
buffer.  Thirty mg wet weight of mitochondrion, thawed on ice, was suspended in 1 
mL of mitochondrial-binding buffer, and then collected by centrifugation at 11,000 × 
g for 5 minutes.  Suspension and centrifugation steps were repeated twice.  The pellet 
was suspended in 1 mL of mitochondrial-binding buffer with added HKI (2 mg/mL), 
protease cocktail inhibitor (0.25 mg/mL) and PMSF (1 mM).  After 60 minutes on ice, 
the mixture of HKI and mitochondria was centrifuged at 11,000 × g for 5 minutes.  
Unbound HKI in the supernatant fluid was decanted.  Pelleted mitochondria were 
suspended in mitochondrial-binding buffer, less the MgCl2, NaCl, and glucose, and 
centrifuged again.  This wash step was twice-repeated. 
HKI-bound mitochondria, prepared as above, is suspended in release buffer 
(250 mM sucrose and 50 mM HEPES, pH 7.4).  50 µL aliquots of this suspension 
were distributed to plastic micro-centrifuge tubes, to which were added a release 
agent (ATP, TNP-nucleotide, or Glc-6-P) at various concentrations.  After 30 minutes 
at room temperature, the mitochondria were pelleted by centrifugation.  HKI 
solubilized by nucleotide was removed by decanting the supernatant liquid.  The 
mitochondrial pellet was suspended in wash buffer (250 mM sucrose and 5 mM 
HEPES, pH 7.4), and centrifuged.  After discarding the supernatant fluid, pelleted 
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mitochondria were suspended in 100 µL wash buffer and then assayed for hexokinase 
activity. 
Results 
 Mitochondria integrity— The outer membrane integrity of the mitochondrion 
preparation was 90% as indicated by the cytochrome c oxidase activity assay (data 
not shown).  Inner membrane integrity was confirmed by mitochondrial uptake of the 
cationic carbocyanine dye JC-1 (data not shown). 
 Rationale for the selection of HKI mutants—Xie and Wilson (46) predicted a 
helical structure for the first 11 residue sequence of rat brain HKI, which was 
confirmed subsequently the structure of the rat HKI (58) (Fig. 3.1).  This sequence is 
identical to that of human brain HKI (Fig. 3.1).  The helical conformation for these 
initial residues puts Ala 4, Ala 8 and Thr 12 on the same face of the helix (Fig. 3.1).  
Other faces of the helix have predominantly residues with large hydrophobic side 
chains.  The alignment of small residues on one face of the N-terminal helix could 
facilitate packing of the helix against a relatively uniform surface of on the β-barrel of 
VDAC1.  If so, then mutations of position 4, 8, and 12 to larger hydrophobic residues 
should decrease the binding of HKI to mitochondria.  The mutation of position 5 to 
proline should destabilize the helix and thereby disrupt mitochondrial association. 
 Size exclusion— Size exclusion chromatography of wild-type HKI and 
mutants (Fig. 3.2) revealed a major band corresponding to a protein of mass 100 kDa 
(Table 3.1). 
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 Fig. 3.1 Structure of HKI.  A. Ribbon of HKI.  The image shows the N-
terminal α-helix with positions 4, 8, and 12 in dark gray.  B. Stick model of the N-
terminal helix (light gray).  Residues targeted for mutation (dark gray) lie on one side 
of the helix.  Model adapted from crystal structure of HKI (PDB ID 1CZA).  C. 
Human brain hexokinase (NCBI Reference Sequence: NP_000179.2) and rat brain 
hexokinase (GenBank: AAC20075.1) aligned by LALIGN (59). 
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Fig. 3.2. Size exclusion chromatography profiles of HKI constructs.  A. Elution profiles of standard proteins. B. Calibration 
curve made from plots log molecular weights of standard proteins logarithm versus retention times.  C. Elution profiles of 
wild-type and mutant HKI.  The concentration of wild-type and mutant HKI was 1 mg/mL.  A sample of volume 100 µL 
was injected onto a TSK-G3000SW type size-exclusion column.  Size exclusion was done in the presence of 5 mM glucose, 
1 mM DTT, and 25 mM KPi, pH 7.4.  Absorbance was monitored at 280 nm. 
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Table 3.1.  Apparent molecular weights of wild-type and mutant hexokinases as 
determined by size exclusion chomatography. 
 HKI construct 
 WT Y10L A4L A8L T12I Q5A Q5P 
MW (kDa) 105 (7) 96 (4) 100 (6) 99 (9) 115 (10) 103 (6) 95 (5) 
Linear regression equation of calibration curve (Figure 1) was used to calculate 
apparent molecular weights of wild type and mutant HKI. Size exclusion was done in 
the presence of 5 mM glucose, 1 mM DTT, and 25 mM KPi, pH 7.4. Absorbance was 
monitored at 280 nm. 
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 HKI and mutants properties— Purified proteins here were at least 95% pure 
on the basis of sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE).  Each hexokinase was prepared twice, and used immediately upon 
purification in mitochondrial binding, gel-filtration and kinetics experiments.  Mutant 
hexokinases have kcat, KmGlc and KmATP comparable to those of wild-type HKI (Table 
3.2).  Edman degradation of wild-type and mutant hexokinases (400 picomole of 
purified enzyme) either provided no sequence information or weak signals for 
sequences beginning at residues 10 and 12.  The vast majority of enzyme molecules 
in each sample had blocked N-terminal residues that resisted Edman degradation.  
Efforts to deformylate the N-terminus by incubation with 0.6 M HCl failed. 
 Wild-type and mutant hexokinase I binding to mitochondria— Scheme I 
represents the simplest equilibrium model that accounts for the binding of wild-type 
and mutant hexokinases to the mitochondria: 
E + Q = EQ,  K1 = [EQ]/[E][Q] 
         Scheme I 
In Scheme I, K1 represents an association constant for the binding of the HKI 
construct (represented by E) to specific mitochondrial binding sites Q.  As 
demonstrated by previous work nonspecific binding to the mitochondrion by HKI 
does not occur at significant levels.  The ratio of enzyme bound to total Eo is as 
follows: 
   R([E]) = (K1[E])/(1+K1[E])       Eq. 1 
The concentration of free specific mitochondrial sites Q is itself a function of the  
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Table 3.2. Kinetic properties of HKI constructs  
HKI construct kcat (s-1) KmATP (mM) KmGlc (µM) 
Wild-type 92 (11) 0.58 (6) 40 (5) 
Y10L 95 (15) 0.54 (4) 19 (3) 
A4L 93 (7) 0.99 (8) 24 (3) 
A8L 103 (15) 0.87 (7) 24 (5) 
T12I 89 (9) 0.57 (5) 23 (4) 
Q5A 98 (10) 0.60 (4) 20 (4) 
Q5P 77 (4) 0.82 (2) 24 (6) 
Determination of kcat employed concentrations of Glc and ATP of 1.6 mM and 9 mM.  
Determination of KmATP employed a Glc concentration of 1.6 µM and concentrations 
of ATP of 0.3–7.5 mM.  Determination of KmGlc employed an ATP concentration of 9 
mM and concentrations of Glc of 10–600 µM. 
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concentration of enzyme.  Algebraic manipulation of the equilibrium expression in 
Scheme I and relationships for mass conservation of total enzyme Eo and total 
specific sites Qo results in a quadratic relationship in E: 
a[E]2 + b[E] + c = 0 
where a = K1, b = K1(Qo–Eo)+1, and c = –Eo.  The physical root of the quadratic 
equation gives [E]: 
 [E] = –{K1(Qo–Eo)+1}/2K1 + {K12(Eo–Qo)2+2K1(Eo+Qo)+1}1/2/2K1       Eq. 2 
Substitution of Eq. 2 into Eq. 1provides a relationship for the fraction of enzyme 
bound to the mitochondria as a function of Eo, Qo and K1. 
The fitting relationship is V = sR(EoQoK1) (Eq. 3), where s is a proportionality 
constant that relates the fraction of bound enzyme R to velocity V in µmoles/min.  
Undefined quantities s, Eo, Qo, and K1 cannot be determined by a nonlinear least 
squares fit of the data from a single experiment.  Hence, values for some of these 
quantities must come from other determinations.  Firstly, one assumes the HKI-
VDAC complex has an equal number of HKI and VDAC subunits.  The value for Qo 
(7.1x10–8 M) then is an estimate based on 42,000 VDAC molecules per 
mitochondrion (60), 7.2x109 mitochodria per 1 mg of total mitochondrial protein (61), 
and 0.014 mg of mitochondria in each 100 µL assay.  Moreover, s = Qo×(specific 
activity)×(assay volume), where the specific activity for HKI is 6x109 µmole/min-1 
mole-1 and the assay volume is liters.  Hence, if the assumption of a 1:1 ratio of the 
HKI-VDAC complex is correct, then data can be fit to Eq. 3 using K1 alone as an 
adjustable parameter.  Data fit by this method appears in Fig. 3.3.  Listed in Table 3.3 
are values for K1 for wild-type and mutant constructs of HKI. 
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 Fig. 3.3. HKI binding to pig liver mitochondria. Plots represent velocities 
from varying concentrations of wild-type (○), T12I (▲), Y10L (■), Q5A (●), Q5P (□), 
A4L (∆) or A8L (♦) bound to 1.8 mg, wet weight  mitochondria (each fraction) in 
250 mM sucrose and 50 mM HEPES, pH 7.5. The solid lines represent fitted curves 
using Eq. 3 with parameters given in the Results section and Table 3.3. 
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Table 3.3. Fitted parameters for wild type and mutant FHKI binding to pig liver 
mitochondria. 
FHKI 
construct 
Apparent dissociation  
constant K1 (M-1) 
WT 2.7 x 104 (6.5 x 102) 
Y10L 1.4 x 104 (7.3 x 102) 
A4L 3.6 x 103 (1.6 x 102) 
A8L 3.5 x 103 (1.5 x 102) 
T12I 2.0 x 104 (7.0 x 102) 
Q5A 8.9 x 103 (4.3 x 102) 
Q5P 4.5 x 103 (1.5 x 102) 
Parameter K1 is defined in the Result section. HKI bound to 1.8 mg, wet weight 
mitochondria (each fraction) in 250 mM sucrose and 50 mM HEPES, pH 7.5 was 
measured by activity. Standard deviations in the last significant digits are given in 
parenthesis. 
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 Glc-6-P induced release of Wild-type and mutant hexokinase I from 
mitochondria— Glc-6-P releases wild-type HKI from mitochondria as well as 
Thr12Ile, Tyr10Leu and Gln5Ala (Table 3.4).  The model and fitting is as described 
previously (41). Release experiments could not be done for the A4L, A8L, and Q5P 
constructs due to poor binding to the mitochondrion. 
 ATP-induced release of Wild-type and mutant hexokinase I from 
mitochondria— ATP released wild-type, Thr12Ile, Tyr10Leu and Gln5Ala 
hexokinases from the mitochondrion likely (Table 3.5 and Fig. 3.4.).  The model and 
fitting is as described in Chapter 2 of this thesis.  Release experiments could not be 
done for the A4L, A8L, and Q5P constructs due to poor binding to the mitochondrion. 
Discussion 
K1 of Scheme I represents binding affinity of HKI for the mitochondrion, but 
binding sites on the mitochondrion may be heterogeneous.  VDAC molecules may 
exist as monomers, dimers, or in assemblies of large number.  Nonetheless each class 
obeys the relationships of Scheme I, provided that HKI binds without cooperativity to 
large aggregates of VDAC.  For a dispersive system, K1 becomes a weighted average 
of association constants for each class of binding site: 
  K1 = (∑iK1[Qi])/∑[Qi] 
where the summations extend over i classes of binding sites with association 
constants iK1 and [Qi] is the concentration of mitochondrial binding sites in each class.  
The effect of site heterogeneity is a K1 that depends on the concentrations of total 
enzyme Eo and mitochondrial sites Qo.  For instance, high ratios of Eo to Qo will 
  
 
 
Table 3.4. Fitted parameters for Glc-6-P-induced release of mitochondrial wild type and mutant HKI. 
HKI construct a 
(µMS-1) 
b 
 
c 
(µM-1) 
Kii 
(mM) 
I0.5 
(µM) 
Relative 
velocity at I0.5 
Limiting 
release 
% 
WT 0.035 (7) 6 (2) 1.1 (4) 0.2 (1) 3 (1) 0.70 (5) 47 (3) 
T12I 0.040 (6) 5 (2) 1.1 (3) 0.3 (1) 2.7 (3) 0.67 (6) 48 (3) 
Y10L 0.028 (4) 4 (2) 0.9 (2) 0.4 (2) 2.8 (4) 0.63 (5) 54 (6) 
Q5A 0.047 (1) 8 (1) 1.5 (1) 0.3 (1) 3.4 (4) 0.74 (2) 40 (2) 
Parameters a, b, c, Kii, and I0.5 previously described (41). Mitochondria with HKI bound in 250 mM sucrose and 50 mM 
HEPES, pH 7.5, were exposed to varying Glc-6-P concentrations for 30 minutes. Remaining mitochondria bound HKI was 
measured by activity. Standard deviations in the last significant digit are given in parentheses.
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Table 3.5. ATP-dependent release of HKI from pig liver mitochondria. 
FHKI construct K1  (M-1) K3  (M-1) 
WT 2.5 x 106 (7.3 x 104) 3.0 x 103 (4.1 x 102) 
T12I 1.7 x 106 (6.3 x 104) 8.0 x 103 (1.2 x 102) 
Y10L 4.9 x 106 (1.9 x 105) 3.0 x 103 (5.0 x 102) 
Q5A 2.4 x 106 (1.0 x 105) 1.0 x 104 (1.7 x 103) 
Parameters are from an equilibrium model in which the binding of nucleotide and 
HKI to the mitochondrion is mutually exclusive.  K1 and K3 are constants for the 
dissociation in M-1 of HKI and ATP from the mitochondrion. Mitochondria with HKI 
bound in 250mM sucrose and 50 mM HEPES, pH7.5, were exposed to varying 
concentrations of ATP for 30 minutes. Remaining mitochondria bound HKI was 
measured by activity. Standard deviations in the last significant digits are given in 
parentheses. 
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 Fig. 3.2. ATP-induced release of wild-type and mutant HKI from pig liver 
mitochondria.  Mitochondria with bound wild type (∆), T12I (○), Y10L (●) or Q5A 
(▲) in 250mM sucrose and 50 mM HEPES, pH7.5, were exposed to varying 
concentrations of ATP . Plots represent relative velocities from mitochondria-bound 
bound HKI that remains after exposure to varying concentrations of ATP. The solid 
lines represent fitted curves using fitting model previously described in chapter 2 of 
this thesis.  
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result in low values for K1, as subclasses of binding sites with low association 
constants contribute to the ensemble average. Wilson et al. (46) have published the 
only binding curve for which the number of mitochondrial binding sites Qo is in great 
excess over Eo.  Applying the model used here to these data yields a K1 of 1.4x106 M-1.  
The number determined from (46) agrees well with the K1 of nucleotide release 
assays (Table 3.5), but is 100-fold higher than the K1 determined from binding assays 
(Table 3.3).  The discrepancy lies in the relative abundance of HKI and mitochondria 
for the release and binding assays.  Specifically for all data points in release assays 
[HKI] ≤ Qo, whereas for binding assays [HKI] ≥ Qo.  The consequence of different 
experimental conditions is a K1 that differs by 100-fold. 
Pittler et. al. (47) proposed that an N-acetyl group blocks the N-terminus of 
native rat-brain hexokinase.  In the present study, the N-termini of wild-type and 
mutant hexokinases resist Edman degradation.  Deformylation of C-terminal His-
tagged human HKI removed the blocking group, resulting in a clear hexokinase 
sequence beginning with the N-terminal methionine (41).  The same procedure, 
however, did not deblock recombinant HKI, used here, which is expressed from a 
vector which does not incorporate a C-terminal His-tag.  There are now many reports 
of recombinant proteins expressed in E. coli with an N-acteyl group at the N-teminus 
(62).  The status of the N-terminus of HKI constructs is critical, because the loss of 
either the blocking group or N-terminal residues could greatly alter the binding 
affinity toward the mitochondrion.  Each of the constructs here has a blocked N-
terminus, and hence, changes in binding properties relative to the wild-type enzyme 
must be a consequence of a specific mutation. 
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Several mechanisms could be responsible for the disruption of HKI binding 
affinity to the mitochondrion.  Mutations could cause global conformational change 
in the protein; however, kinetic parameters clearly indicate active enzyme with wild-
type properties.  Moreover, the removal of residues from the N-terminus has no effect 
on the kinetic properties of HKI (or hexokinase Type-II) from human and other 
sources (63,64).  Mutations could also change the state of aggregation of HKI, and 
thereby impede association with the mitochondrion, but constructs here are 
monomers up to peak concentrations used in mitochondrial binding assays.  Hence, 
decreased binding affinities observed here are due the effect of the mutation on the 
specific interactions with the mitochondrion. 
Although HKI binds to hydrophobic surfaces (48), specific binding of HKI to 
mitochondria cannot be explained merely by hydrophobic interactions with a lipid 
bilayer (46).  Mutations at positions 4 and 8 identify the first single-residue 
determinants essential for the interaction of HKI with the mitochondrion.  The loss of 
binding properties due to the Gln5→Pro mutation infers a helical conformation for 
the N-terminal residues of mitochondrion-bound HKI.  Hence, positions 4 and 8 
define a contiguous surface that does not allow large residues, even if these residues 
are hydrophobic.  Other positions seem less important, and allow conservative 
changes in the type of amino acid side chain, but no mutation improved mitochondrial 
binding. 
Cyclic AMP-dependent protein kinase, D-AKP1, binding to mitochondria and 
endoplasmic reticulum is also controlled by a 15-residue N-terminal sequence 
homologous to that of HKI (52).  Small hydrophobic side chains on residues 
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corresponding to residues Ala4 and Ala8 in HKI tail are necessary for mitochondrial 
targeting (52).  Moreover, the amount of HKI that binds to the mitochondrion 
diminishes as residues are removed from the N-terminal sequence (51).  Thr12 is on 
the same helical face as Ala4 and Ala8, but the mutation of position 12 to isoleucine 
has less impact on mitochondrial binding properties of HKI; however, the steric bulk 
at position 12 increases by only single methyl group, whereas positions 4 and 8 have 
additions of isopropyl groups.  Ala4 and Ala8 are not likely critical for lipid 
interactions, but would define a relatively flat surface on the N-terminal helix.  Such a 
surface would pack favorably against a flat exterior surface of the β-barrel of VDAC.  
Preliminary coarse grain modeling (Yang Gao and Richard Honzatko, unpublished 
results) indicates a preferred placement of the surface defined by positions 4 and 8 on 
the barrel of VDAC.  This placement puts the N-terminal domain of HKI over the 
opening of the anion pore of VDAC, consistent with the channel-blocking properties 
of HKI. 
Although N-terminal residues are essential for HKI association with the 
mitochondria, one cannot exclude the possibility of other residues elsewhere on HKI 
playing an essential role (65).  Nucleotide (Chapter 2) and Glc-6-P (41) release of 
mitochondrion-bound HKI implicate the pore of VDAC and the Glc-6-P binding 
pocket of the N-terminal half of HKI in the VDAC-HKI recognition.  If VDAC favors 
an open conformation for the N-terminal half of HKI, then Glc-6-P could disrupt 
essential contacts by driving the N-terminal domain to its closed conformation.  The 
binding of nucleotides to VDAC could alter the conformation of the pore, disrupting 
the same VDAC-HKI interactions.  Finally, the N-terminal hydrophobic helix of HKI 
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continues beyond residue 15 and becomes highly charged with acid and basic side 
chains.  Some of these charged residues are in position to interact with VDAC.  Given 
the current work establishes a method of quantifying the effects of a mutation on 
mitochondrion binding affinity, one can systematically mutate residues suggested by a 
HKI-VDAC model to locate additional residues on HKI critical to mitochondrion-
binding. 
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CHAPTER 4: TRINITROPHENYL NUCLEOTIDE ANALOGS 
BINDING TO WILD-TYPE AND MUTANT HUMAN BRAIN 
HEXOKINASES16  
A paper to be submitted to the Journal of Biological Chemistry 
Nimer Mehyar2 and Richard B. Honzatko2,37 
Abstract 
 Fluorescent nucleotide analogue 2′,3′-O-(2,4,6-trinitrophenyl) adenosine 5′-
diphosphate (TNP-ADP) binds with high affinity to the active site of HKI.  
Nucleotides displace TNP-ADP from HKI with different efficiencies.  Adenosine 5′-
triphosphate (ATP) is the most potent displacement nucleotide.  Magnesium divalent 
ion (Mg2+) has no effect on TNP-ADP binding to HKI.  Glucose affects TNP-ADP 
binding to HKI, and also affects it displacement by glucose 6 phosphate (Glc-6-P). 
TNP-ADP binding to HKI under kinetic assay conditions is weaker that under 
fluorescence assay conditions.  Results here are consistent two conformations of HKI 
in slow equilibrium.  One conformation binds TNP nucleotides with high affinity, but 
under conditions of assay HKI adopts a conformation that binds TNP nucleotides with 
less affinity. 
Introduction 
 Hexokinase (ATP: D-hexose-6-phosphotransferase, EC 2.7.1.1) catalyzes first 
step of glycolysis.  Hexokinases catalyze the use of ATP to phosphorylate glucose at 
                                                 
1This research was supported in part by National Institute of Health Research Grant 
NS 10546 
3To whom correspondence should be addressed. 
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its 6-hydroxyl position (1).  Mammals have four isoenzymes: I, II, III, and IV (2).  
Although hexokinases (I-III) have similar molecular weights (~100 kDa) and share 70% 
sequence identity (3) they have distinct kinetic properties (4).  Brain hexokinase (HKI) 
is the major isoenzyme in brain tissue and red blood cell (5).  The primary 
physiological inhibitor of the Type-I enzyme is glucose 6-phosphate (Glc-6-P) (6). 
Under normal physiological conditions, inorganic orthophosphate (Pi) is capable of 
relieving inhibition by Glc-6-P (4).  At high concentrations, Pi can bind to the active 
site and inhibit HKI (7).  Hexokinase II (HKII) is functionally similar to HKI; 
however, Pi does not relieve Glc-6-P inhibition of the Type-II (3) or Type-III (8) 
isoenzymes.  Hexokinases have evolved by the duplication and fusion of a primodial 
hexokinase gene similar to that of yeast hexokinase (9).  The Glc-6-P binding site has 
evolved putatively from a primordial catalytic site (3).  Both halves of HKII support 
catalysis and are each sensitive to inhibition by Glc-6-P (10), whereas only the C-
terminal half of HKI supports activity (11).  Glc-6-P binds to either half and inhibits 
activity (12-13).  Pi allosterically relieves Glc-6-P inhibition by binding with high 
affinity to the N-terminal half of HKI (14-15). 
HKI and HKII associate with the outer mitochondrial membrane in brain 
tissue (16).  This interaction requires fifteen, largely hydrophobic amino acid residues 
at its N-terminus (17).  HKI association with outer mitochondrial membrane allows 
preferential access to newly formed mitochondrial ATP (16).  HKI likely interacts 
with the voltage-dependent anion channel (VDAC) of the outer mitochondrial 
membrane (18-19).  HKI binding to the mitochondrion prevents the opening of the 
permeability transition pore (PTP) (20).  Opening of the PTP results in loss of 
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membrane potential, organelle swelling, cytosolic acidification, and release of 
cytochrome c (20-21).  Cytochrome c that escapes the mitochondrion activates the 
caspase family of proteases, which ultimately results in apoptosis (22-24).  
Mitochondrion-associated hexokinase II clearly antagonizes the action of pro-
apoptotic factors such as Bax (25-27).  A number of small and physiological 
important ligands are capable of dissociating HKI from the mitochondrial outer 
membrane.  Skaff et al. (28) demonstrated the significance of Glc-6-P binding to the 
N-terminal half of HKI in promoting the release of the mitochondrion-associated 
enzyme.  The Glc-6-P release phenomenon adheres to a simple equilibrium model.  
ATP-induced release of HKI from mitochondria (16,29-31) is linked to nucleotide 
binding to VDAC (Chapter 2, this thesis). 
Glucose 6 phosphate inhibition of HKI is explained by two models.  Glc-6-P 
competes with ATP for the active site of HKI (32-36) or alternatively, Glc-6-P inhibits 
HKI by binding to the N-half of the enzyme (37-41).  The three dimensional structure 
of human HKI revealed two almost identical binding sites for Glc-6-P at the C- and 
N-terminal halves (15,42-44).  Mutational analysis revealed that both sites bind Glc-
6-P with high affinity and each site can inhibit HKI (13).  To date, no experiment has 
clearly ruled out either model for Glc-6-P inhibition. 
Human HKI has up to three adenine nucleotide binding sites: the active site at 
the C-terminal half (11), the Pi binding site at the N-terminal half at which the 
nucleotide may bind through its terminal phosphoryl group (42), and the nucleotide 
pocket of unknown function near the N-terminal membrane targeting element 
identified by x-ray crystallography (42,45).  Since there is no three dimensional 
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structure of HKI with ATP in the active site, homology with yeast hexokinase and 
other nucleotide binding proteins was used to develop a model for ATP binding (46).  
Several residues at the HKI active site were tested by site directed mutation, some 
were shown to have a crucial role in stabilizing the transition state (39,47-48); 
however, none of the mutations eliminated ATP binding completely.  Mutations in the 
vestigial nucleotide binding site at N-half caused significant loss of Pi-induced relief 
of Glc-6-P inhibition (48).  Although [ATP-Mg]2- is the true substrate for HKI, the 
enzyme can uses Mg2+ complexes of other triphosphate nucleosides, albeit less 
efficiently (49).  ATP4- (50-51) and other pyrimidine nucleotides (52) compete with 
[ATP-Mg]2- for the active site of HKI.  In addition to binding to the active site, purine 
nucleotides, particularly ADP, can also inhibit HKI allosterically (4,32,50-54).  In 
contrast to kinetic data, HKI-bound flourescent nucleotide analog tetraiodofluorescein 
(TIF), a competitive inhibitor versus [ATP-Mg]2-, is competitively displaced by ATP, 
ADP and Glc-6-P (55).  Fluorescent nucleotide analogs proved to be a useful tool to 
study yeast hexokinase inhibition mechanisms and measure the specificity of different 
inhibitors toward HKI (56).  The purpose of this paper is to use trinitrophenyl 
nucleotides to measure ligand specificty toward HKI. 
Experimental Procedures 
 Materials—ATP, ADP, AMP, GDP, CDP, 2'-deoxy-ATP, glycerol-3-phosphate, 
chloramphenicol, deoxyribonuclease (DNase I), bovine serum albumin (BSA), 
leupeptin, protease cocktail inhibitor and phenylmethylsulfonyl fluoride (PMSF) 
came from Sigma.  Kanamycin sulfate was purchased from Invitrogen.  TNP-ATP, 
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TNP-ADP and TNP-AMP came from Invitrogen.  TNP-CTP came from Jena 
Biosciences. DEAE HPLC resin was a product of Tosohaas.  Nickel-nitrilotriacetic 
acid-agarose (NiNTA) resin and Rosetta (DE3) competent cells were from Novagen.  
Glucose-6-phosphate dehydrogenase was obtained from Roche Molecular 
Biochemicals.  Isopropyl-1-thio-β-D-galactopyranoside (IPTG) came from Anatrace.   
 Construction of Wild-type Hexokinase and Mutant Plasmids—Human brain 
hexokinase (HKI) had been cloned into pET-24b with a 10-residue histidine tag at its 
C-terminus as reported in a previous study (28).  Full length HKI (57), mHKI (46), 
triple mutant HKI: E280 A, R283A, and G284Y (42), α + 2 HKI and N384R HKI (28) 
were all available from previous studies.  Hexokinase mutants were created through 
PCR modification with oligonucleotide primers synthesized at the Iowa State 
University DNA Sequencing and Synthesis Facility. 
 Truncated HKI was created by introducing a NdeI cut site before Thr12 in the 
pET24b-HKI-10-histidine tag using the following forward primer (and its reverse 
compliment): 
5’CTCCTGGCCTATTACTTCACGGAGCATATGGATGACCAGGTCAA 
AAAGATTGA-3’.  Mutated plasmid was digested with NdeI and then ligated to 
produce pET24b-truncated HKI with a 10-histidine tag.  This plasmid encodes a 
truncated tail form of HKI starting from residue 12.  G747 and S788M were prepared 
using the following forward primers and their reverse complements: 5'-
GGTATGAGAAGATGAT CAGTCTGATGTACCTGGGTGAAATCGTC-3' for 
G747L and 5'GAGACCAAGTTT CTCATGCAGATC GAGAGTGACCGA-3' for 
S788M. 
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 Expression and Purification of Wild-Type HKI and N-domain HKI— Wild-
type or mutant HKI plasmids were transformed into E.coli strain Rosetta (DE3).  
Expression and purification HKI enzymes are discussed in detail by Skaff et al (28).  
Determination of protein concentrations employed the Bradford method with bovine 
serum albumin as a standard (58). 
 The HKI Activity Assay— Hexokinase activity was measured using the 
glucose 6-phosphate dehydrogenase (G6PDH)-coupled spectrophotometric assay.  
Assay solutions have 3 mM MgCl2, 3 mM DTT, 6 mM ATP:Mg2+, 1.6 mM Glucose, 
0.3 mM NADP and 10 µg/mL G6PDH in 50 mM Tris-HCl, pH 8.0.  NADPH 
production velocity was monitored at 340 nm wavelength.  Reactiosn were initiated 
by the addition of enzyme.  Linear reaction progress curves were monitored for 3 
minutes, the slopes of which were used to calculate initial rates.  When the amount of 
HKI was doubled, reaction rate was also doubled without affecting the linearity of the 
reaction.  Initial rate data were analyzed using GraFit (59).  TNP-nucleotide inhibition 
was measured using the same assay conditions. 
 HKI  fluorescence experiments— Prior to the experiment, purified HKI and 
hVDAC-1 were dialyzed twice against 50 mM Tris-HCl, pH 7.5, and 2 mM glucose.  
SLM Amico 8000 fluorometer was used to measure fluorescence in a 1-cm2 quartz 
cuvette.  Fluorometer entrance and exit slit widths were set at 4 nm.  Experiments 
were done at room temperature.  TNP-ADP was exited at 409 nm and emission was 
scanned between wavelengths 450 to 600 nm.  Fluorescence titrations were 
performed by successive addition of small volumes of TNP-ADP to 1 mL of 2.5 µM 
HKI, and then the emission spectrum was scanned three times.  Total added titrant 
95 
 
volume did not exceed 5% of the total volume.  Displacement experiments were 
performed by accumulative addition of nucleotide to 1 mL of 2 .5 µM HKI and 1µM 
TNP-ADP solution.  Total volume of added nucleotide did not exceed 5% of the total 
volume. Observed fluorescence was corrected for titrant dilution.  Fallar (60) 
approach to Analysis of fluorescence data followed the approach of Fallar (60), using 
a single-site binding model described in Chapter 2 of this thesis and GraFit for 
nonlinear least squares fitting. 
RESULTS 
 TNP-nucleotides binding to Wild-type and mutant HKI and displacement by 
ATP and other nucleotides— Binding of ATP and TNP-ADP to HKI is mutually 
exclusive.  ATP displaces HKI-bound TNP-ADP.  Observed fluorescence as a result 
of TNP-ADP binding to HKI is the summation of fluorescence from free ligand, 
bound ligand, and protein (HKI), that is Fobs=Ffree+Fbound+Fprotein.  Parameters KA , 
KL,γ and Fprotein were used for fitting.  These parameters are defined in Chapter 2 of 
this thesis.  Analog TNP-ADP binds with high affinity to wild type HKI and Hisis-tag 
HKI equivalently (Table 4.1) and also ATP displaces TNP-ADP efficiently from 
constructs (Table 4.1). ADP, AMP, 2'-deoxy-ATP, and GDP, displace TNP-ADP from 
wild type HKI (Table 4.2), but CDP and glycerol-3-phosphate do not.  Trinitrophenyl 
nucleotides (TNP-ATP, TNP-ADP, TNP-AMP and TNP-CTP) bind to wild-type HKI 
similarly, and all are displaced by ATP (Table 4.3). 
 TNP-nucleotides inhibit wild type hexokinase I— Wild-type HKI (kcat=73±4 s-
1,
 KmGlc=77±6 µM, and KmATP=1.1±0.1 µM) was used in these experiments.  When 
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ATP was replaced by TNP-ADP under assay conditions where free Mg2+ levels are 2 
mM, no product evolution was observed even for prolonged times (data not shown).  
All TNP-nucleotides compete with ATP causing enzyme inhibition (KiTNP-ATP=4.5±0.4, 
KiTNP-ADP=4.9±0.5, KiTNP-AMP=4.7±0.6, KiTNP-CTP=2.6±0.2). 
 Glc-6-P displacement of TNP-nucleotides bound to wild-type HKI— Neither 
Glc-6-P nor glucose affect TNP-ADP fluorescence in the absence of HKI (data not 
shown).  Glc-6-P displaces TNP-ADP bound to wild-type HKI (Fig. 4.1).  In the 
presence of glucose, Glc-6-P displaces TNP-ADP more effectively (no glucose, 
KA=480±50 µM versus 2 mM glucose, KA=6.3±0.9 µM).  Glucose has little effect on 
TNP-ADP binding affinity (no glucose, KL=2.1±0.2 µM versus 2 mM glucose 
KL=0.78±0.8 µM) (Fig. 4.2) or ATP displacement of TNP-ADP (no glucose, 
KA=170±20 µM, versus 2 mM glucose  
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Table 4.1.  TNP-ADP and ATP binding to HKI constructs in the presence of 50 µM Glc-
6-P. 
HKI Construct KL (µM) KA (mM) γ Fprotein 
Wild-typea 3.6 (5) 0.49 (6) 12.3 (4) 0.032 (2) 
Wild-type 4.9 (8) 1.0 (1) 27 (1) 0.022 (4) 
Triple 2.7 (4) 1.2 (1) 13.5 (4) 0.019 (2) 
Truncateda 3.6 (4) 1.7 (2) 13.1 (4) 0.021 (2) 
α+2a 1.4 (1) 1.2 (1) 8.1 (2) 0.010 (2) 
N384Ra 1.4 (3) 1.5 (3) 8.4 (3) 0.011 (3) 
mHKIa 4.9 (7) 0.9 (1) 28 (1) 0.027 (4) 
Parameters are from a single binding site model.  KL, KA,γ and Fprotein are respectively 
the dissociation constant for TNP-nucleotide (TNP-ADP), the dissociation constant 
for displacing ligand (ATP), fluorescence enhancement factor attributed to the bound 
versus free state of the TNP-nucleotide, and the intrinsic fluorescence from the 
protein.  Fluorescence was measured at varying total concentrations of TNP-
nucleotides and ATP in 2 mM glucose, 50 µM Glc-6-P and 50 mM Tris-HCl, pH 7.5.  
Standard deviations in the last significant digits are given in parentheses. 
 
aC-terminal His-tagged construct. 
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Table 4.2.  TNP-nucleotide binding to wild-type C-terminal His-tagged HKI. 
TNP-nucleotide KL (µM) KA (µM) γ Fprotein 
TNP-ATP 1.2 (2) 130 (20) 11.7 (3) 0.003 (1) 
TNP-ADP 0.78 (9) 190 (20) 14.8 (3) 0.017 (2) 
TNP-AMP 0.5 (1) 130 (30) 14.3 (5) 0.012 (2) 
TNP-CTP 0.75 (3) 110 (10) 13.9 (4) 0.032 (2) 
Parameters are from a single binding site model.  KL, KA, γ and Fprotein are as defined 
in Table 4.1  Fluorescence was measured at varying total concentrations of TNP-
nucleotides and ATP in 2 mM glucose and 50 mM Tris-HCl, pH 7.5.  Enzyme 
concentration is 2.5 µM wild-type C-terminal His-tagged HKI.  Standard deviations 
in the last significant digits are given in parentheses. 
 
Table 4.3.  Displacement of TNP-ADP from wild-type HKI by different nucleotides. 
 Nucleotide 
Parameter ATP ADP AMP GDP GMP 
KL (µM) 0.78 (9) 0.73 (7) 0.8 (1) 0.67 (8) 0.65 (8) 
KA (µM) 190 (20) 260 (20) 810 (80) 5000 (700) 7000 (1000) 
γ 11.7 (3) 15.0 (2) 14.8 (3) 15.1 (3) 15.1 (3) 
Fprotein 0.003 (1) 0.015 (2) 0.018 (2) 0.014 (2) 0.014 (2) 
Parameters are from a single binding site model.  KL and KA, are constants for the 
dissociation of TNP-ADP and nucleotide indicated in the column heading from wild-
type HKI.  Fprotein and γ are defined in Table 4.1.  Fluorescence was measured at 
varying total concentrations of TNP-nucleotides and ATP in 2 mM glucose and 50 
mM Tris-HCl, pH 7.5.  Enzyme concentration is 2.5 µM C-terminal His-tagged HKI.  
Standard deviations in the last significant digits are given in parentheses. 
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 Fig. 4.1.  Effect of glucose on TNP-ADP displacement by Glc-6-P.  Plots are 
fluorescence at varying total concentrations of Glc-6-P added to 2.5 µM wild-type C-
terminal His-tagged HKI and 5 µM TNP-ATP, 50 mM Tris, pH 7.5, plus 2 mM 
glucose (○) or 0 mM glucose (▲).  Solid lines represent fitted curves using 
parameters KA, KL, γ and Fprotein as defined in Table 4.1.  Parameters values are in 
results section. 
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 Fig. 4.2.  Effect of glucose on TNP-ADP binding.  Plots are fluorescence at 
varying total concentrations of TNP-ADP in 50 mM Tris-HCl, pH 7.5, with no protein 
(▲), wild-type C-terminal His-tagged HKI 2.5 µM plus 2 mM glucose (●) or plus 0 
mM glucose (○).  The solid lines represent fitted curves using parameters KL, γ and 
Fprotein.  Parameters values are listed in the results section. 
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KA=190±20 µM).  50 µM Glc-6-P weakened TNP-ADP binding to wild-type HKI (50 
µM Glc-6-P, KL=3.6±0.5 µM versus no Glc-6-P, KL=0.8±0.1) and weakened the 
binding of other nucleotides (no Glc-6-P, see Table 4.3 versus 50 mM Glc-6-P, 
KAATP=500±60 µM, KAADP=1800±300 µM, KAAMP=6000±1000 µM, KAdeoxy 
ATP
=800±100 µM, KAGDP=5000±2000 µM) (Fig. 4.3).  Glycerol-3-phosphate and 
CDP do not displace TNP-ADP. 
 pH and Mg2+ effects on TNP-ADP binding and displacement— Neither pH 
nor MgCl2 affect TNP-ADP fluorescence in the absence of HKI (data not shown).  
When 2mM glucose is present, binding affinity of TNP-ADP to wild type HKI 
slightly increased as the pH increased to 8.0 (Fig. 4.4) (pH 8, KL=0.27±0.07 µM 
versus pH 7.5 KL=0.8±0.1).  Raising the pH to 8.0 did not affect TNP-ADP 
displacement by ATP (KA=140±30 µM) or Glc-6-P (KA=6.2±0.5 µM).  In the absence 
of glucose, adding Mg2+ did not affect TNP-ADP binding to wild-type HKI 
(KL=2.5±0.2 µM, γ=11.5±0.2, Fprotein=0.013±0.001) (Fig. 4.5). 
 TNP-ADP binding to hexokinase I mutants G747L and S788M and 
displacement by ATP and Glc-6-P— Catalytic activity of mutants G747L and S788M 
decreased significantly compared to the wild-type HKI; however, binding affinities 
for the substrates were not affected (Table 4.4).  TNP-ADP binding is not affected by 
S788M (KLTNP-ADP=1.6±0.2 µM, γ=9.7±0.2, Fprotein=0.032±0.001).  Mutant G747L 
binds to TNP-ADP with significantly less affinity (KLTNP-ADP=22±7 µM, γ=19±3, 
Fprotein=0.030±0.003) (Fig. 4.6).  Glc-6-P concentrations required to displace TNP-  
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 Fig. 4.3.  Effect of Glc-6-P on nucleotide displacement of TNP-ADP.  Plots 
are the fluorescence at varying total concentrations of different nucleotides:  ATP (●), 
ADP (□), AMP (♦), 2'-deoxy-ATP (▲), GDP (∆), CDP (■), and glycerol-3-phosphate 
(○) added to 2.5 µM wild-type C-terminal His-tagged HKI and 5 µM TNP-ATP, 2mM 
glucose, 50 mM Glc-6-P and 50 mM Tris buffer, pH 7.5.  The solid lines represent 
fitted curves using parameters KA, KL, γ and Fprotein  Parameters values are listed in 
results. 
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 Fig. 4.4.  Effect of pH on TNP-ADP binding to wild-type HKI.  Plots 
represent the fluorescence at varying total concentrations of TNP-ADP in 50 mM 
Tris-HCl with no protein (▲), wild-type C-terminal His-tagged HKI 2.5 µM, pH 7.5 
(●) or pH 8.0 (○).  The solid lines represent fitted curves using parameter KL,γ and 
Fprotein.  Parameter values are listed in the results section. 
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 Fig. 4.5.  Mg2+ effect on TNP-ADP binding to wild-type HKI.  Plots represent 
the fluorescence at varying total concentrations of TNP-ADP in 50 mM Tris-HCl, pH 
7.5, with no protein (▲), wild-type C-terminal His-tagged HKI 2.5 µM plus 2 mM 
MgCl2 (○) or 0 mM MgCl2 (●).  Solid lines represent fitted curves using parameter 
KL ,γ and Fprotein.  Parameter values are listed in results section. 
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Table 4.4.  Kinetic parameters for wild-type and mutant HKI constructs. 
HKI mutant kcat (s-1) KmATP (mM) KmGlc (µM) 
G747L 2.7 (4) 1.1 (1) 200 (10) 
S788M 17 (3) 3.8 (6) 110 (10) 
Assays are described in the experimental section.  Determination of kcat employed 
mutant C-terminal His-tagged HKI and concentrations of Glc and ATP of 1.6 mM and 
9 mM.  Determination of KmATP employed a glucose concentration of 1.6 µM and 
concentrations of ATP of 0.3–7.5 mM.  Determination of KmGlc employed an ATP 
concentration of 9 mM and concentrations of glucose of 10–600 µM. 
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 Fig. 4.6. Titration of wild type HKI and mutants G747L and S788M with 
TNP-ADP.  Plots represent the fluorescence at varying total concentrations of TNP-
ADP in 2 mM glucose and 50 mM Tris-HCl pH 7.5, with no protein (▲), wild-type 
HKI 2.0 µM (●), G747L HKI 2.0 µM (○),and S788M HKI 2.0 µM (◊).  All HKI 
constructs have C-terminal His-tags.  The solid lines represent fitted curves using 
parameters KL, γ and Fprotein  Parameters values are listed in results. 
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Table 4.5.  TNP-ADP and ATP binding to mutant HKI. 
HKI mutant 
KLTNP-ADP 
(µM) 
KAATP 
(µM) 
KAGlc-6-P 
(µM) 
γ Fprotein 
G747L 22 (7) 300 (200) 130 (70) 19 (3) 0.030 (3) 
S788M 1.6 (2) 1400 (100) 5.1 (7) 9.7 (2) 0.032 (1) 
Parameters are from a single binding site model.  Kd, KAATP,γ and Fscatter are constants 
for the dissociation in µM of TNP-nucleotides. Fluorescence was measured at varying 
total concentrations of TNP-nucleotides and ATP in 2 mM glucose and 50 mM Tris-
HCl pH 7.5.  Enzyme concentration is 2.5 µM mutant C-terminal His-tagged HKI.  
Standard deviations in the last significant digits are given in parentheses. 
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ATP increased significantly for mutant G747L and was not affected for mutant 
S788M (Table 4.5).  TNP-ADP displacement by ATP is twofold weaker for mutant 
G747L and ten-fold weaker for mutant S788M (Table 4.5). 
Disscusion 
 Trinitrophenyl nucleotides bind to wild-type human HKI as previously 
reported (Chapter 2, this thesis).  The TNP-ADP binding site on HKI does not involve 
the His tag or residues at the N-terminus involved in the binding of HKI to 
mitochondria.  Tight binding of TNP-ADP to N384R HKI indicates that the N-
domain ADP site revealed by crystallography (42) is not a binding site for the TNP-
nucleotide.  Triple mutant HKI (E280A, R283A, and G284Y) does not dimerize even 
at high concentrations of protein (42).  TNP-ADP binding to triple mutant HKI 
eliminates the possibility a binding site stabilized by dimerization.  Mini-HKI, an 
active construct consisting of the C-terminal half and transition helix (46), binds to 
the probe as does wild-type HKI.  These data are consistent with a binding site on the 
C-terminal half of HKI.  This agrees with previous reports of weak binding of TNP-
ADP to N-domain HKI (Chapter 2, this thesis).  Competitive inhibition behavior of 
TNP-nucleotides with respect to ATP identifies the HKI active site as a potential 
binding site for TNP-nucleotides (Chapter 2, this thesis).  In contrast to yeast 
hexokinase (56) different TNP-nucleotides showed no variation in binding affinity or 
inhibition of wild-type HKI.  The involvement of nitrophenyl group in binding TNP-
nucleotides to wild-type HKI cannot be disregarded.  TIF, a fluorescent molecule 
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binds specifically to rat HKI (55) and has similar structural and chemical properties 
as the nitrophenyl group. 
A ten-fold difference between Ki and KL was observed for all TNP-nucleotides.  
Although the published TIF inhibition of HKI (Ki=25 µM) (61) matches TIF binding 
affinity to HKI (KL=15 µM) with a 6- to 7-fold fluorescence enhancement (55), the 
model used to fit fluorescence data in that study does not correct the observed 
fluorescence for contributions from free fluorophore and protein (62).  Fitting the data 
from reference (55) with the model used in this study resulted in an enhancement 
factor (γ=7.5) and a binding affinity (KL=1.7 µM).  The difference between the 
reported TIF Ki and the TIF KL is more than ten-fold, and similar to the difference 
reported here for TNP-ADP Ki and KL.  What is the cause of significant differences in 
Ki from kinetics and KL from fluorescence titrations? 
Three conditions are different between kinetic and florescence assays: (i) pH, 
(ii) presence of Mg2+ and (iii) length (duration) of the assay.  Raising the pH of the 
fluorescence assay to that of the kinetic assay (pH 8.0) slightly decreases KL for TNP-
ADP and makes the discrepancy more significant.  The addition of Mg2+ to 
fluorescence titrations does not affect TNP-ADP binding to wild-type HKI, and 
similarly, does not affect TNP-ATP binding to yeast hexokinase (56) or TIF binding 
to rat-brain hexokinase (55).  The combination of Mg2+ and ATP in the kinetics assay, 
however, generates [ATP-Mg]2-, which is not present in fluorescence titrations.  In 
comparison to magnesium chelates of other nucleoside triphosphates, [ATP-Mg]2- is 
most effective in protecting the C-terminal half of rat-brain hexokinase against tryptic 
digestion (55,65).  In the absence of Mg2+, ATP, UTP, CTP and GTP protect 
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hexokinase equally (65) and Mg2+ alone does not protect hexokinase against tryptic 
digestion (38).  Indeed, [ATP-Mg]2- is the favored substrate of HKI and could well 
stabilize HKI in a conformation less favorable for the binding of TNP-ADP.  
Moreover, fluorescence titrations compared to activity assays expose HKI to TNP-ADP 
for long times.  If the binding of TNP-ADP requires a slow conformational change in 
HKI that is antagonized by [ATP-Mg]2-, then the tight binding affinity observed in 
fluorescence titrations may not be observed in kinetics (Fig. 4.7). 
 
 
 Figure 4.7.  Proposed model for TNP-ADP binding to HKI. 
 
 
Adenosine triphosphate displaced TNP-ADP from wild type most efficiently. 
Removing 2'-hydroxyl group did not affect ATP binding, however, removing the γ 
phosphoryl or both γ- and β-phosphoryl groups attenuates ATP binding significantly.  
Nitrogen bases contribute to nucleotide binding specificity.  Purines displace TNP-
ADP from wild-type HKI better than pyrimidines.  A phosphotriose is unable to 
compete with TNP-ADP as measure by the lack of displacement by glycerol-3-
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phosphate.  Nucleotide binding specificity observed in this study matches the 
inhibition specificity observed in kinetics studies (52).  TNP-ADP displacement by 
ATP is consistent with a model of mutual exclusion.  Kinetics investigations indicate 
ATP4- is a competitive inhibitor with respect to substrate [ATP-Mg]2- (52).  Baijal and 
Wilson (55) report that ATP, ADP or ATP plus ADP displaced 50-70% of bound TIF 
from HKI.  Due to the partial displacement of TIF and lack of accumulative effect of 
ATP plus ADP these authors concluded that ADP displaces TIF competitively by 
binding to the active site.  Corrections for fluorescence contributions from high 
concentrations of HKI (6-12 µM) and free fluorophore were not made in reference 
(55), and without such corrections dissociation constants are erroneously high and 
estimates of displacement are erroneously low. 
ADP displacement data in the current study does not rule out the possibility of 
ADP binding to a second binding site; however, binding to such a site does not 
displace TNP-ADP.  This does not agree with kinetic data, which indicate two binding 
sites for ADP consistent with a model of mixed inhibition (51).  The previously 
proposed model (Fig. 4.7) can also explain the different response to ADP in kinetic 
assays versus fluorescence assays.  In this model, ADP binds effectively only to the 
active site of E* conformation, on the other hand, ADP can effectively bind to both 
active and allosteric sites of E conformation. 
Glc-6-P displaces TNP-ADP from wild type HKI efficiently in the presence of 
glucose.  Removing glucose significantly decreases Glc-6-P displacement of TNP-
ADP.  Glc-6-P also displaces TIF from rat brain hexokinase (55).  This agrees with 
previously observed synergistic binding of glucose and Glc-6-P (11,36).  Glc-6-P 
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displacement of TNP-ADP from wild-type HKI can be explained either by direct 
competition for the active site or by the binding of Glc-6-P to an allosteric site at the 
N-terminal half of HKI. 
The mutation G747L introduces a bulky side chain in the putative ribosyl-
binding pocket of ATP.  Not surprisingly this mutation increases KL for TNP-ADP by 
as much as 100-fold (using KL for TNP-ADP in the presence of glucose); however, 
the mutation decreases Glc-6-P affinity (KA rises 25-fold compared to wild-type HKI), 
but has little effect on ATP affinity.  Gly747 is part of a structural element that may 
play a central role in the allosteric (N-terminal half) mechanism of Glc-6-P inhibition 
of HKI.  Hence, the displacement of TNP-ADP by Glc-6-P may be due to the binding 
of Glc-6-P to the N-terminal half, rather than the direct binding of Glc-6-P to the C-
terminal half.  The absence of a significant effect on the KA for ATP indicates that 
ATP can bind (the Km for ATP also is unaffected by the G747L mutation), but that the 
binding differs in some way from the catalytically productive mode (kcat is diminished 
by 98%).  The mutation S788M introduces a bulky side chain in the base-binding 
pocket of ATP.  This mutation has little effect on the affinity of TNP-ADP, no effect 
on Glc-6-P affinity and but decreases ATP affinity (KA rises 8-fold compared to wild-
type HKI).  These observations can be reconciled if the base of TNP-ADP does not 
occupy the base-binding pocket of ATP.  Hence, the data here suggest TNP-ADP, and 
presumably other TNP-nucleotides are not analogs of ATP, but that they still bind at a 
site that is subject to the action of Glc-6-P as an allosteric inhibitor.  A detailed 
understanding of TNP-ADP binding could provide important insights regarding the 
mechanism of allosteric Glc-6-P inhibition. 
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CHAPTER 5: GENERAL CONCLUSIONS 
This study provides the mechanism of nucleotide release of HKI from the 
mitochondrion.  TNP-ADP and ATP significantly released HKI from the 
mitochondrion in the absence of Mg2+.  HKI does not utilize TNP-nucleotides as 
substrates.  Consequently TNP-ADP release is not due Glc-6-P production.  TNP-
ADP is a competitive inhibitor of HKI with respect to ATP.  TNP-ADP competes with 
ATP4- and ATP-Mg2- for a binding at the C-terminal half of HKI.  TNP-ADP binding 
to the N-terminal half of HKI is weak or absent altogether, and yet TNP-ADP releases 
both wild-type and N-domain HKI from the mitochondrion.  Evidently, the binding 
site for TNP-ADP at the C-terminal half is also not responsible for HKI release from 
the mitochondrion.  Hence, TNP-ADP release of HKI must be due to its binding to 
the mitochondrion. 
VDAC-1 is a possible mitochondrion binding site for nucleotides.  TNP-
nucleotides bind to VDAC-1 similarly high affinities.  They are also equally effective 
in the release of HKI from the mitochondrion.  ATP displaces TNP-ADP from 
VDAC-1 and also releases HKI from mitochondria.  CDP is unable to displace TNP-
ADP from VDAC-1, and it is also unable to displace HKI from the mitochondrion.  
The VDAC-1 binding site for TNP-nucleotides strongly interacts with the TNP 
moiety.  The base and phosphoryl groups of TNP-nucleotides seem to play a 
secondary role in the high-affinity association of these nucleotides.  ATP seems more 
effective that ADP in the release of HKI from the mitochondrion, indicating some 
preference for the triphosphoryl over the diphosphoryl group. 
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TNP-nucleotides competitively inhibit HKI and are equally effective in 
binding and inhibition.  Evidently, the nitrophenyl group plays a dominant role in 
interactions with HKI.  The TNP-ADP dissociation constant measured by 
fluorescence is 10-fold smaller than the inhibition constant determined by activity 
assays.  The difference could be attributed to conformational states of HKI that are 
mutually exclusive, one favoring interactions with TNP-nucleotides and the other 
favoring the substrate [ATP-Mg]2- of HKI.  These two conformations of HKI would 
necessarily be in slow exchange. 
In agreement with synergistic binding of glucose and Glc-6-P to HKI, Glc-6-P 
displaces TNP-ADP from HKI more effectively in the presence than in the absence of 
glucose.  Displacement of TNP-ADP can be explained by the binding of Glc-6-P to 
the active site or to the N-terminal half allosteric site.  The reduction Glc-6-P binding 
affinity in the mutant G747L HKI, a mutation outside of the C-terminal half binding 
pocket for Glc-6-P, indicates TNP-ADP displacement by Glc-6-P may be by the 
allosteric mechanisms.  The absence of a significant effect on the dissociation 
constant of TNP-ADP due to the S788M mutation indicates the base-binding pocket 
of ATP is not used by TNP-ADP.  TNP-ADP then is not an analog of ATP, but binds at 
a site at the C-terminal half that is sensitive to the allosteric action of Glc-6-P. 
Loss of mitochondrial binding properties due to the loss of the 15 N-terminal 
residues of rat-brain HKI suggests that one or more of these residues are necessary for 
the binding of HKI to the membrane.  No single-residue determinant of HKI 
mitochondrial-binding are known, this study reports two residues are essential for 
binding.  Selective mutations amongst the first 15 residues have no effect on kinetic 
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properties of HKI, and wild-type and mutant enzymes behave identically as 
monomers in solution.  The N-terminus in all constructs is block by unknown 
functional group that prevents sequencing by Edman degradation.  Mutant enzymes 
A4L and A8L do not bind to the mitochondrion.  These residues define a contiguous 
surface of the N-terminal helix of HKI.  That surface does not tolerate large 
hydrophobic side chains, indicating a close contact between it and a mitochondrial 
binding partner (VDAC-1). 
The work here provides a new (displacement of TNP-ADP for VDAC-1), 
which can be used in a high-throughput screen for molecules that displace TNP-ADP 
from VDAC-1.  These molecules should also displace HKI from the mitochondrion, 
and indeed, molecules are currently known that do displace HKI from mitochondrion, 
but the mechanism by which these molecules function is unknown..  Work here also 
defines a surface of contact between HKI and VDAC-1 that can serve as a basis for 
modeling the complex of VDAC-1 with HKI.  That model should predict additional 
points of interaction that can be confirmed by mutation. 
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